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Abstract 
The beneficial effects of estrogen include lowering of low-density lipoprotein 
cholesterol and decreased vascular contractility. However, the precise pathways, and 
the cellular mechanisms by which female sex steroid hormones influence the activity 
of various vasculatures are incompletely understood. An increasing amount of 
evidence suggests that nitric oxide production, modulation of the vascular 
responsiveness to endogenous vasoconstrictors or vasodilators may play an important 
role in the vascular effects of female sex steroid hormones. 
I specifically proposed the following hypotheses to be examined. (1) Endothelial 
nitric oxide may play a differential role in relaxation of arteries of different diameters 
induced by estrogen and progesterone. (2) P-Adrenoceptor agonists and 17p-estradiol 
may exert mutual synergistic effects on vessel tone. (3) Acute exposure to 
physiological level of 17P-estradiol may modulate p-adrenoceptor-mediated 
vasorelaxation. (4) Chronic treatment with 17p-estradiol may alter the vascular 
contractility. To this end, the experiments were carried out on several types of isolated 
rat arteries (e.g. aorta, mesenteric, and carotid artery) and on porcine coronary artery. 
I have demonstrated that 17p-estradiol induced both endothelium-dependent 
and -independent relaxation in rat aortic rings, but only endothelium-independent 
relaxation in rat mesenteric arteries. In contrast, progesterone induced both 
endothelium-dependent and -independent relaxation in mesenteric arteries, but only 
endothelium-independent relaxation in rat aortas. N*^ -nitro-L-arginine methyl ester 
(L-NAME, 30 |LIM) and methylene blue (3-10 ^ M) attenuated relaxation induced by 
� 
np-estradiol in aortas or to progesterone in mesenteric arteries. L-arginine (1 m M ) 
significantly antagonized the effect of L - N A M E on sex hormones-induced relaxation. 
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I have provided novel evidence for the synergistic interaction between (3-
adrenoceptor agonists and 17p-estradiol. 17p-Estradiol-induced relaxation was 
enhanced by 1-hr pretreatment with 1-3 n M isoproterenol, a p-adrenoceptor agonist. 
This effect was absent in endothelium-denuded mesenteric artery rings. Propranolol 
(3 |iM)’ a P-adrenoceptor antagonist reduced the effect of isoproterenol (1 nM). ICI 
118, 551, a pi-adrenoceptor antagonist abolished the effect of isoproterenol. In 
contrast, atenolol, a Pi-adrenoceptor antagonist had no effect. Besides, fenoterol, a p2-
adrenoceptor agonist, also potentiated 17p-estradiol-induced relaxation. Incubation of 
endothelium -intact arteries with L-NAME and Rp-cAMPS triethylainine, an inhibitor 
of cAMP-dependent protein kinase, abolished isoproterenol enhancement of 17^-
estradiol-induced relaxation. Rp8-pCRT-cGMPS triethylamine, an inhibitor of 
cGMP-dependent protein kinase la, significantly attenuated the effect of 
isoproterenol. 
Short-term (20 minutes) or longer (1 hr) exposure to 17p-estradiol (0.1-1 nM) 
did not modify isoproterenol- and dobutamine-induced relaxation in most 
concentrations of (3-adrenoceptor agonists tested. However, 1-hr exposure to 0.3 n M 
np-estradiol significantly potentiated relaxation produced by fenoterol in porcine 
coronary circumflex arteries. Tamoxifen (10 |iM) antagonized this effect. 
To study the chronic effect of 17p-estradiol, the rats were ovariectomized and 
divided into four groups, e.g. the ovariectomized, the ovariectomized plus estrogen 
replacement, the ovariectomized plus tamoxifen replacement, and the ovariectomized 
plus 17p-estradiol and tamoxifen replacement groups. I have clearly revealed a 
� 
marked change in vascular contractility following ovariectomy. In the endothelium-
denuded rat carotid arteries, the contractile responses to phenylephrine, U46619, or 
high K:+ were significantly enhanced in the ovariectomized rats. This enhancing effect 
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was completely reversed by estrogen therapy or was absent in endothelium-intact 
rings. Chronic treatment with tamoxifen (implanted pellet) had a similar effect to 17(3-
estradiol pellet. In contrast, acetylcholine-mediated relaxation was unaffected. 
In summary, I have provided some novel findings concerning the arterial effects 
of female steroid hormones. Firstly, endothelial nitric oxide plays different role in 
relaxant response to 17P-estradiol and progesterone in the conduit vessel (aorta) and 
smaller-sized vessels (mesenteric artery). Endothelial nitric oxide contributes largely 
to endothelium-dependent relaxation induced by 17p-estradiol in the aortas or by 
progesterone in the mesenteric arteries. Secondly, 17p-estradiol-induced relaxation in 
mesenteric arteries was enhanced by isoproterenol via p2-adrenoceptor activation. L-
N A M E or Rp-8-cGMPS eliminated or markedly inhibited the effect of isoproterenol, 
suggesting that isoproterenol may act on the endothelial cells to release nitric oxide 
and cGMP-dependent pathway was involved. A cAMP-dependent mechanism in 
endothelium was also involved in the effect of isoproterenol These new findings 
suggest that Pi-adrenergic agonist and 17p-estradiol can synergies each other via 
several intracellular second messengers primarily in endothelium. Thirdly, both 17p-
estradiol and progesterone concentration-dependently reduced the contractile response 
to the activator of protein kinase C, indicating an additional cellular mechanism by 
which steroid hormones reduce vessel tone evoked by PKC-dependent constrictors 
such as phenylephrine, endothelin and angiotensin 11. Fourthly, acute exposure to 
physiological level of 17p-estradiol enhanced p2-adrenoceptor-mediated coronary 
relaxation. Finally, ovariectomy and chronic 17p-estradiol altered the vascular 
reactivity mainly in endothelium-denuded arteries. These data suggest that chronic 
• treatment of 17 (3-estradiol may modulate the properties of smooth muscle but not of 
endothelial cells. 
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N^-nitro-L-arginine methyl ester (L-NAME)禾口 guanlyate cyclase 抑制劑 methylene 
blue都可抑制np-雌二醇和黃體酮引起之血管舒張。而L-arginine則能拮抗L-
N A M E之作用。 
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致的血管舒張°去除血管內皮細胞能抑制異丙腎上腺素的作用。若在使用異丙 
腎上腺素之前，先加進propranolol (非特異性卩賢上腺能受體抑壓劑）或ICI 
118,551 (p2賢上腺能受體抑壓劑)都可抑制雌二醇引致作用。但是atenolol (pi賢 
上腺能受體抑壓劑)則沒有作用°另外’ fenoterol (p.賢上腺能受體激動劑)也有 
助雌二醇引致的血管舒張°另一方面，在內皮細胞完整的血管，預處理L.-
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Chapter 1 Introduction 
1.1. Steroid Hormones 
Hormones can be divided into three groups on the basis of chemical structure: (1) 
amino acid-related hormones, (2) peptides and protein hormone, and (3) steroid 
hormones. Their chemical nature, such as, where it is derived, how it is carried in the 
blood and its cellular mechanism of action are different. 
In mammalian systems, there are seven groups of steroid hormones that can be 
classified on both a structural and biological basis. They are (1) androgens, (2) 
estrogens, (3) glucocorticoids, (4) mineralocorticoids, (5) progestagens, (6) vitamin D 
steroids, and (7) bile acids (Norman & Litwack, 1997). 
All steroid hormones are lipids that are derived from cholesterol. Except vitamin 
D steroids, the basic structure of all other steroids has a 
cyclopentanoperhydrophenanthrene ring as their core, which is shown in Figure la. 
Since it is derived from cholesterol and synthesized on smooth endoplasmic reticulum, 
steroid hormones are non-polar and fat-soluble. Due to these properties, once steroid 
hormones are produced, they simply diffuse across the plasma membrane of the 
steroid-producing cell and enter the interstitial fluid and then the blood. Therefore, 
glandular storage of steroids is minimal. They are not readily soluble in blood and 
hence are transported bound to proteins. Furthermore, these compounds are absorbed 
fairly in the gastrointestinal tract and therefore they can be administered orally. 
� 
IJ.L Synthesis of estrogens and progesterone 
The estrogens are a group of hormones, which include estrone (Ei), estradiol (E2) 
and estriol (E3). At least six different estrogens have been isolated from the plasma of 
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human females (Tortora and Grabowski, 1996). However, only three are present in 
significant quantities: estrone, 17p-estradiol and estriol. 
In non-pregnant females, estrogens are produced in follicular cells of ovaries 
under the control of gonadotrophin from the anterior pituitary, follicle stimulating 
hormone (FSH). FSH stimulates the initial secretion of estrogens by converting the 
cholesterol to pregnenolone, which is then converted to androstenedione or testosterone, 
in some cases via progesterone. Testosterone is then converted to 17p-estradiol by 
aromatase enzymes. Few days before ovulation, another gonadotrophin, luteinizing 
hormone (LH) stimulates the further development of ovarian follicles and their full 
secretion of estrogen brings about ovulation and promotes formation of the corpus 
luteum. On the other hand, adipose tissue also expresses aromatase enzymes and is 
therefore able to convert androgens to estrogens. In males and postmenopausal females 
adipose tissue is the major source of estrogen. 
Meanwhile, the mature follicles produce a small amount of progesterone several 
days before ovulation. After ovulation, the major source of progesterone is the cells of 
corpus luteum. It is derived from cholesterol via pregnenolone under the action of 
3p-steroid dehydrogenase (Norman & Litwack，1997). The function of progesterone in 
this phase is to synergies with estrogens to prepare the endometrium for implantation of 
a fertilized ovum. Moreover, high levels of progesterone may give negative feedback to 
hypothalamus and anterior pituitary to inhibit secretion of gonadotropin releasing 
hormone and LH. 
In this study, I focused on examining the vascular effects of two steroids: 
17p-estradiol and progesterone. The chemical structures of these two steroids are 
shown in Figure lb and Ic. The synthetic route for the conversion of cholesterol to 
estrogens and progesterone is shown in Figure 2. These two steroids have commonly 
been used in contraception (Pharmaceutical Society of Australia, 1998) and hormone 
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The chemical structures of (a) cyclopentanoperhydrophenanthrene, (b) 17p-estradiol 
and (c) progesterone. 
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Cholesterol 
+ ① . 
Pregnenolone 
Progesterone 17a-hydroxypregnenolone 
17a-hydroxyprogesterone Dehydroepiandrosterone (DHEA) 
Androstenedione Aetiocholanone 
/ Testosterone 




The synthetic route for the conversion of cholesterone to estrogens and progesterone by 
the ovaries. The circled numbers represent the key enzymes involved in the process.① 
desmolase;② 3p-steroid dehydrogenase;③ 17a-hydroxylase;④ aromatase. 
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replacement therapy in postmenopausal women for several decades (Stampfer et al, 
1991; Grady et al, 1992; Godsland, 2001). 
1.2. Cellular Mechanisms of Female Steroid Hormones 
Steroids can act through two basic mechanisms: genomic and non-genomic. The 
classical genomic action is mediated by specific intracellular receptors, whereas the 
primary target for the non-genomic one is the cell plasma membrane. In the following, 
estrogen is taken as an example to explain these two mechanisms in cardiovascular 
system. 
1.2.1. Genomic actions of female steroid hormones 
Once steroid hormone particles are combined with sex hormone-binding globulin 
(SHBG) after synthesis, they are carried to the target cells. In cardiovascular system, 
estrogen receptor was found in both endothelium and vascular smooth muscle of blood 
vessels (Horwitz and Horwitz, 1982). After chronic exposure of estrogen, it binds to the 
intracellular receptors. The estrogen-receptor complex then binds to specific D N A 
sequences and estrogen response elements (EREs), resulting in altered transcription of 
specific m R N A and subsequent protein synthesis. For example, prolonged estrogen 
treatment increases m R N A for endothelial nitric oxide synthase (NOS), which suggests 
that increased N O S activity results from enzyme induction and an increase in protein 
synthesis (Goetz et al., 1994; MacRitchie et al, 1997). This elevation of N O S may 
increase production of nitric oxide (NO), which then diffuses to the underlying vascular 
smooth muscle. In addition, smooth muscle N O S may also be increased by estrogens, 
explaining the genomic modulation of endothelium-denuded vascular tone that has 
recently been observed (Binko et al., 1998; Binko & Majewski，1998) (Figure 3). 
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Figure 3 
The proposed genomic mechanisms by which vessel tone may be altered following 
chronic estrogen exposure. These involve an increased synthesis of endothelial N O S 
and release of N O from endothelium. Moreover, inducible N O S in smooth muscle may 
also be increased by estrogen, explaining the genomic modulation of 
endothelium-denuded vascular tone (Binko et al, 1998; Binko & Majewski, 1998). 
cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; ER, 
estrogen receptor; GC, guanylate cyclase; GTP, guanosine triphosphate; iNOS, 
inducible nitric oxide synthase; L-Arg, L-arginine; PKG, cGMP-dependent protein 
kinase. 
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1.2.2. Non-genomic actions of female steroid hormones 
In contrast to genomic steroid action, non-genomic steroid effects are principally 
characterized by their insensitivity to inhibitors of transcription and translation 
(actinomycin D and cycloheximide). For example, it is reported that inhibitors of 
protein and R N A synthesis have no effect on the acute endothelium-independent 
vasodilatory effects of estrogens in a number of different vessels (Kitazawa et al, 1997; 
Shaw et al., 2000). This rapid and acute responses generally appear to be 
endothelium-independent, which has been shown in a wide range of arteries, such as rat 
aorta (Andersen et al, 1999)，rat mesenteric and coronary arteries (Shaw et al” 2000) 
and rabbit coronary arteries (Jiang et al, 1991). However, there is evidence that acute 
exposure to estrogen may also alter the eNOS activity. It has been described that acute 
application of 17p-estradiol increases the eNOS activity via a Ca-"'-dependent 
mechanism (Shaul, 1999) (Figure 4). 
On the other hand, a number of studies reported that progesterone also exerts a 
non-genomic action. For example, progesterone at micromolar concentrations induced 
concentration-dependent relaxations of the isolated rat saphenous artery rings within 10 
minutes (Kakusc et al； 1998). Moreover, progesterone caused coronary relaxation by 
inhibiting Ca^ "" entry through voltage-gated Ca'"" channels in coronary smooth muscle. 
Besides, 17P-estradiol and testosterone have a similar action (Crews & Khalil，1999). 
1.2.3. Estrogen antagonists 
1.2.3.1 Classification of estrogen antagonists 
Steroid antagonists can be either steroidal analogues or nonsteroidal compounds 
that function as selective inhibitors of steroid hormone action. According to MacGregor 
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nucleus GTP cGMP / 0( / 
\ Z J z / \ j / 
PKG J K+ 
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Figure 4 
The proposed non-genomic mechanisms underlying the acute vasodilator effect of 
estrogen. These involve (1) Stimulation of N O release via increased [Ca^^i in 
endothelial cells. (2) Inhibition of voltage-operated Ca^^ channels (VOCC) and thus a 
decrease in [Ca^^i in vascular smooth muscle. (3) Activation of K+ channels, 
membrane hyperpolarization and subsequent inhibition of Ca^^ influx through V O C C 
in vascular smooth muscle. cGMP, cyclic guanosine monophosphate; eNOS, 
endothelial nitric oxide synthase; ER; estrogen receptor; GC, guanylate cyclase; GTP, 
guanosine triphosphate; L-Arg, L-arginine; NO, nitric oxide; PKG, cGMP-dependent 
protein kinase; VOCC, voltage-operated Ca^ "^  channels. 
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and Jordan, estrogen antagonists are divided into two major groups: type I and II 
(MacGregor & Jordan，1998). 
Type I estrogen antagonists include those compounds that exhibit mixed 
estrogenic and anti-estrogenic actions. These compounds are also called selective 
estrogen receptor modulators (SERMs) (Sato et al., 1994). S E R M s are structurally 
diverse non-steroidal agents that bind to both estrogen receptor a (ERa) and p (ERp) 
receptors, and produce estrogen agonistic effects in some tissues and estrogen 
antagonistic effects in others (Sato et al,, 1994). The action of these compounds is 
thought to be tissue- and species-specific. For example, tamoxifen is anti-estrogenic in 
breast tissues (Jordan & Morrow, 1999)，but it causes endometrial stimulation and 
increases the likelihood of endometrial cancer (Barakat, 1996; Barakat, 1998). Due to 
this characteristic, S E R M s are being evaluated for a number of estrogen-related 
diseases, including hormone-related cancers, postmenopausal osteoporosis and 
cardiovascular disease. The most commonly used drugs that exhibit a S E R M property 
for clinical use are tamoxifen, raloxifene, clomiphene and toremifene. 
Type II estrogen antagonists are free of estrogen-like properties in laboratory 
assays. These compounds can be considered as pure anti-estrogenic agents because 
their action is not tissue- and species-specific. They always exert antagonistic effects in 
all estrogen-targeted tissues, such as the mammary tissue, uterus and bones (Gradishar 
and Jordan, 1997). The most commonly used drugs of this group are ICI 182,780 and 
ICI 164,384. Table 1 tabulates the compounds falling into these two categories. 
1.2.3.2. Mechanisms of estrogen antagonists. 
� 
Type I antagonists are competitive inhibitors of the binding of estradiol to estrogen 
receptor. For example, raloxifene binds to estrogen receptor, which retains partial 
transcription activity (Brzozowski et al., 1997). However, type 11 antagonists bind to 
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estrogen receptor to prevent the complex binding to EREs (Fawell et ai, 1990). 
Table 1 Classification of estrogen antagonists 
Type I (SERMs) Type II (Pure anti-estrogen) 
Tamoxifen ICI 182,780 
Raloxifen ICI 164,384 
Clomiphene R U 58688 
Toremifene EM-800 
EM-139 
1.3. Chronic (genomic) Effects of 17p-Estradiol and 
Progesterone 
1.3.1. Effects on lipid metabolism 
Estrogens protect against the development and progression of atherosclerosis 
(Walsh et al, 2000). The best known beneficial effect of estrogens on coronary heart 
disease (CHD) risk is the lipid hypothesis. It was first reported in 1987 that estrogens 
affected the lipoprotein profile by increasing high-density lipoprotein (HDL) 
cholesterol levels and decreasing low-density lipoprotein (LDL) cholesterol level 
(Bush et al” 1987). 
Recent studies have revealed that estradiol acts separately on the LDL particle and 
the artery wall to reduce LDL accumulation (Walsh et al., 2000). It was found that 
estradiol protects LDL from modification and subsequent accumulation due to its 
antioxidant property (Walsh et al., 2000)，although the underlying mechanism is still 
unclear. Many biomedical and cell culture studies demonstrate that estrogen acts to 
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scavenge oxygen radicals in order to protect L D L from oxidative modification 
(Mooradian, 1993; Rifici and Khachadurian, 1992). However, some other studies 
suggest that estradiol within physiological concentrations may not function as an 
antioxidant (Santanam et al, 1998). 
Moreover, estradiol decreases basal L D L accumulation by decreasing arterial 
permeability in rats (Walsh et al, 2000). Paradoxically, other investigators found that 
estrogen did not affect aortic permeability to L D L in rabbits (Haarbo et al, 1994), 
indicating a species difference. 
On the other hand, progesterone has a similar function to estrogen on lipid 
metabolism. It was reported that treatment of postmenopausal women with 
levonorgestrel (a kind of progesterone) resulted in a reduction of the serum 
concentration of HDL2 by 20 %. Moreover, the concentrations of total triglycerides, 
total phospholipids, HDL, HDL2, HDL-phospholipids and apolipoprotein Al were 
decreased by 10 to 30 % (Kuusi et al, 1993; Kauppinen-Makelin et al, 1992). 
13,2, Effects on cell proliferation 
The protective effect of estrogen in animals against vascular injury is partly 
mediated by its anti-proliferative effect on vascular smooth muscle cells. Smooth 
muscle cells (SMC) proliferation is an important process after blood vessels were 
injured (Ross and Glomset, 1973; Clowes et al., 1983). In 1977，it was reported that 
estrogen suppressed surgically induced vascular hyperplasia in the rabbit aorta (Rhee et 
a/.，1977). Later on, more experiments provided further evidence for the inhibitory 
effect of estrogen on S M C proliferation. Myointimal thickening after mechanical or 
lipid-induced damage of the vessel wall can be attenuated markedly following 
17p-estradiol treatment (Nishigaki et al., 1995). In cell culture experiments, it was 
found that 17P-estradiol inhibited proliferation of rabbit aortic S M C stimulated with 
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hyperlipedemic serum (Fisher-Dzoga et al., 1983). Another set of experiments showed 
similar results in cultured human vascular S M C (Morey et al, 1997), in which estrogen 
inhibited the mitogen-activated protein kinases (MAPK) and M A P K kinases (MEK) 
activity and stimulated c-fos and c-myc expression. These findings suggest that 
estrogen can suppress growth factor-induced vascular S M C proliferation and thus 
prevents thickening of the vascular wall. 
1.3.3. Effects on endothelial cells 
Estrogen does not only target on SMC, but also exerts potent biological effects on 
the endothelial cells. In vivo studies, estrogen can accelerate re-endothelialization in 
carotid arteries of ovariectomized rat, which was implanted estradiol-pellets after 
arterial injury (Krasinski et al, 1997). Later on, supplementary data have indicated that 
this process is likely mediated through estrogen receptor-a but not estrogen receptor-p 
(Brouchet et al., 2001). 
Morales et al. reported that estrogen had a potent effect on endothelial cell 
migration and proliferation (Morales et al., 1995). Using either a Boyden chamber 
assay or scratching a monolayer of endothelial cells, three-fold increases in cell 
migration were observed. In addition, estrogen-treated cells migrated into the wound 
three times faster than untreated cells after a confluent monolayer of cells was wounded 
by scraping (Morales et al, 1995). Estrogen receptor antagonist ICI 182,780 inhibited 
the effect of estrogen. This process is important in the angiogenesis, because new blood 
vessel formation involves migration of the endothelial cells (Folkman, 1995). 
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1.4. Acute Effects of 17p-Estradiol and Progesterone 
1.4.1. Role of endothelium in 17f^-estradiol or progesterone relaxation 
Estrogen receptors have been identified in both endothelium and the underlying 
vascular smooth muscle and they are thus physiological targets for estrogen action 
(Orima et al, 1995). Nitric oxide and other endothelium-derived vasoactive factors are 
potent vasodilators which release is stimulated by many endogenously occurring 
substances. 1713-Estradiol mediated endothelium-dependent vasodilatation was studied 
in the past. 17P-Estradiol reduced vasoconstriction in the endothelium-denuded rat 
aortas probably through inducible production of nitric oxide (Binko & Majeweki, 1998). 
It has been reported that an enhanced vasodilator response in female rat aorta was 
abolished by endothelium removal (McNeill et al, 1996). After long-term treatment of 
estrogen, aortic rings with intact endothelium were super-sensitive to noradrenaline, 
but such results did not occur in endothelium-denude rings (Moura & Marcondes, 
2001). However, conflicting results have also been reported regarding the role of 
endothelium in vasodilatation induced by female sex steroid hormones. For example, 
nitric oxide was partly involved in the estrogen-induced relaxation in the rabbit aorta 
(Ma et al, 1997), but not in the rabbit coronary arteries (Jiang et al.’ 1991). Preliminary 
data from our laboratory demonstrate that nitric oxide contributes largely to the 
endothelium-dependent relaxation induced by 17p-estradiol in the rat aortas but not in 
the rat mesenteric arteries (Chan et al, 2001a). 
On the other hand, the role of endothelium in progesterone relaxation remains 
unclear. Our results showed that progesterone caused vasorelaxation in rat 
endothelium-intact mesenteric arteries but not in endothelium-denuded rings (Chan et 
a/.’ 2001a). However, progesterone was found to induce only endothelium-independent 
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relaxation in rabbit coronary arteries (Jiang et al.’ 1992b). The cause of the difference 
between results obtained from two research groups is not known but it may be related to 
difference in experimental animal species. 
1.4.2. Involvement of plasma membrane estrogen receptors 
In 1977，evidence was provided to show that a plasma membrane estrogen binding 
protein rapidly responded to estradiol (Pietras & Szego, 1977). Since then, many 
functional studies on the rapid, non-genomic effects of 17p-estradiol have supported 
for the existence of the membrane estrogen receptor. Estrogen can trigger intracellular 
Ca2+ spikes in endothelial cells (Rubio-Gayosso et al” 2000), increases Ca""" efflux in 
vascular smooth muscle cells (Prakash et al, 1999), stimulates adenylate cyclase 
(Aronica et al., 1994) in a few seconds to minutes. The membrane estrogen receptor 
might also be involved in regulation of transcription, considered being the primary 
function of the nuclear estrogen receptor (Halachmi et al., 1994). 
At the same time, membranous binding of fluorescently labeled 
membrane-impermeant estrogen has been demonstrated in endothelial cells (Pyo et al.’ 
1999) and in pituitary tumor cells (Pappas et al” 1995)，which further supports for the 
presence of plasma membrane estrogen receptor. 
1-4.3, Role ofCa^^ channel and FC channel in estrogen relaxation 
As mentioned in Section 1.4.2” estrogen modulates Ca^ "" influx through 
membrane estrogen receptor. In smooth muscle cells, acute administration of 
np-estradiol produced inhibition of L-type voltage-operated Ca^ "" currents recorded 
� 
with patch-clamp technique (Nakajima et al” 1995), and a decrease in intracellular 
calcium concentration ([Ca2+]i) (Shan et al., 1994). Ivp-Estradiol also inhibited B A Y K 
8644 (a dihydropyridine derivative which opens voltage-dependent Ca^ "" 
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channels)-induced elevation of [Ca^ J^i (Prakash et al., 1999). In contrast, estrogens 
have no effect on Ca^^ release from intracellular stores in vascular smooth muscle 
(Kitazawa et al, 1997). Therefore, it is concluded that the acute 
endothelium-independent vasodilatory response to estrogen is partly due to inhibition 
of Ca2+ influx across the plasma membrane of vascular SMC. 
Apart from inhibition of the Ca^^ channels, activation of K+ channels may also 
contribute to the estrogen-mediated vasorelaxation. 17(3-Estradiol was shown to 
activate large conductance Ca^ -^activated (BKca) and voltage-activated K"^  channels 
through a cGMP-dependent mechanism, thus indirectly reducing Ca^ "" influx (White et 
al, 1995). However, 17a-estradiol had no effect. 
On the other hand, the effect of estrogen on Ca^ "" influx in other cell types is 
opposite to that in smooth muscle cells. It has been shown that 17p-estradiol induced a 
fast increase in [Ca^^i in rat osteoblast (Lieberherr et al., 1993), hepatocytes 
(Sanchez-Bueno et al., 1991), and vascular endothelial cells (Rubio-Gayosso et al” 
2000). Besides, 17p-estradiol was found to enhance the formation of inositol 
1,4,5-triphospate through increased phospholipase C activity (Picotto et al, 1999). In 
isolated female rat colonic crypts, IVP-estradiol increases by opening of L-type 
voltage-operated Ca^ "^  channels (Doolan et al., 2000). 
L4.4. Interaction with vasoconstrictors 
In addition to the direct effects of estrogens on the vasculature, they may also 
regulate muscle contractility via interaction with other vasoconstrictors. One of the 
examples is the interaction of estrogen with renin-angiotensin system, which is targeted 
� 
therapeutically in the treatment of hypertension. It was reported that estrogen inhibited 
angiotensin Xl-induced constrictor effect both in vitro and in vivo. In isolated tissue 
studies, chronic estrogen treatment has been shown to down regulate angiotensin 
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Il-receptor expression in the anterior pituitary and adrenal cortex (Carriere et al., 1986). 
Moreover, angiotensin Il-induced contraction was significantly depressed in vascular 
rings from 17P-estradiol-treated rats, which was independent of the presence of the 
vascular endothelium (Cheng & Gruetter, 1992). In vivo studies showed that 
17p-estradiol treatment attenuated contractile responses to exogenous angiotensin II 
(Magness et al” 1993). 
The interaction between estrogen and endothelin-1 was also investigated. 
Estrogen attenuated endothelin-1-induced vasoconstriction in the isolated rabbit 
coronary arteries (Jiang et al, 1992a). Moreover, estrogen inhibited endothelin-1 
production and secretion from cultured bovine aortic endothelial cell (Morey et al,, 
1998) and human vascular endothelial cells (Wingrove & Stevenson, 1997). In vivo 
studies, acute administration of physiological concentrations of estradiol attenuated 
endothelin-1-induced vasoconstriction in both porcine coronary conductance and 
resistance arteries (Sudhir et al, 1997). 
The effects of estrogen on other vasoconstrictors were also examined. Massicotte 
et al, reported that pregnancy reduced pressor responses to arginine 8-vasopressin 
(Massicotte et ai, 1987), it is due to prolong exposure to high level of plasma estrogen. 
However, there are contradictory results on the norepinephrine response. Although 
Shan et al. found that 17|3-estradiol decreased the pressor responses to norepinephrine 
in male rats (Shan et al., 1994), but enhanced responsiveness to norepinephrine has 
been described in aortic rings from prepubertal and ovariectomized rats pretreated with 
np-estradiol (Cheng & Gruetter, 1992). 
� 
L4,5, Interaction with endothelium-dependent dilators 
As described in Section 1.4.1.，endothelium plays a role in estrogen-induced 
relaxation, the interaction between estrogen and endothelium-dependent dilators will 
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be discussed. NO, one of the endothelium-dependent dilators, the underlying is the key 
transducer of a vasodilator message from the endothelium to the underlying vascular 
smooth muscle cells (Schulz & Triggle, 1994). In cultured bovine endothelial cells 
(BAEC), acute 17P-estradiol increased the eNOS activity via a Ca-"'-dependent 
mechanism (Goetz et al., 1999). It is proposed that 17p-estradiol induces subcellular 
translocation of eNOS and this suggests a role of estrogen in the modulation of 
NO-dependent vascular tone. 
It was also reported that estrogen may interact with acetylcholine, another 
endothelium-dependent vasodilator. Ovariectomized monkeys receiving 17p-estradiol 
demonstrated a vasodilator response to acetylcholine, while monkeys not receiving 
hormone replacement showed a vasoconstrictor response to acetylcholine (Williams et 
fl/.’ 1990). In addition, chronic treatment of estrogen increased the dilating sensitivity 
of the guinea pig coronary microcirculation to acetylcholine (Thompson et al., 2000). 
Furthermore, incubation with 17p-estradiol enhanced relaxations to bradykinin, 
an endothelium-derived vasodilator locally produced by endothelial cells, in isolated 
human coronary arteries (Barton et al., 1998). However, conflicting results were 
presented. It is reported that short-term exposure of 17p-estradiol did not affect the 
endothelium-dependent relaxation induced by bradykinin and A23187 (a calcium 
ionophore) in porcine coronary artery, both agents stimulate N O synthesis (Teoh et al.’ 
1999). 
1.4,6, Interaction with adrenergic response 
Estrogen modulates the adrenergically mediated vascular responses. For example, 
the depressant effect of estrogen treatment on the relaxant response to noradrenaline in 
the rabbit femoral artery was prevented by the (X2-adrenergic antagonist, rauwolscine 
(Gisclard et al., 1987). Noradrenaline-induced relaxation of coronary arteries was 
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enhanced by acute, direct exposure to physiological levels (10"^  M ) of 17P-estradiol. 
This enhancement is not due to the effect of 17p-estradiol to suppress a-adrenergic 
contraction to noradrenaline or to increase coronary p-adrenergic receptor sensitivity 
(Bell et al., 1995). On the other hand, estrogen replacement in the ovariectomized rats 
enhanced vasoconstriction induced by endothelial a2-adrenoceptor activation via an 
increased release of constricting prostaglandins in mesenteric arteries (Ferrer & Osol, 
1998). 
The relaxation induced by isoproterenol was impaired in ovariectomized rats and 
estrogen substitution restored the |3-adrenergically-mediated relaxation (Ferrer et al, 
1996). In non-vascular smooth muscle from female rabbit detrusor, estrogen treatment 
resulted in increased relaxant responses mediated by P2- and Ps-adrenergic receptor 
subtypes, which may be related to the increased cyclic A M P content (Yono et al., 2000). 
Estrogen was found to sensitize the isoproterenol-induced rat aortic relaxation probably 
through nitric oxide- and cytochrome P-450-dependent metabolites (Honda et al., 
1998). p-Adrenoceptor-mediated vasorelaxation is thought to be mediated at least in 
part via cyclic AMP-dependent mechanisms (Gray & Marshall, 1992; Delpy et al, 
1996; Toyoshima et al” 1998) or by endothelium-dependent pathway (Graves & Poston, 
1993; Huang & Kwok, 1997; Huang et al., 1998). Estrogen-induced vasorelaxation 
may involve cyclic AMP-mediated pathway (Teoh & Man, 2000). In the cardiac 
myocytes, a low concentration of 17(3-estradiol (1 nM) reduced isoproterenol-induced 
increase in whole-cell L-type voltage-dependent Ca^ "" currents (Meyer et al, 1998). It 
remains, however, elusive whether estrogen potentiation of the isoproterenol-induced 
relaxation is due to synergistic interaction on cyclic AMP-dependent mechanism or on 
up-regulation of p-adrenoceptors in vascular smooth muscle cells. If there exists a 
crosstalk linkage between different intracellular signaling pathways activated by 
estrogen and (3-adrenoceptor agonists, it is reasonable to hypothesize that isoproterenol 
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may be also able to amplify the relaxant response to ivp-estradiol. Indeed, 
isoproterenol-induced enhanced responses (heart rate and systolic pressure) to estrogen 
in rat hearts involved a cyclic AMP-dependent mechanism (Li et al., 2000). These data 
indicate that estrogen and isoproterenol could mutually exert synergistic interaction 
with each other. However, the mechanism responsible for P-adrenoceptor-mediated 
amplification of estrogen-induced vasorelaxation has yet to be explored. 
1.5. Clinical Studies 
Since the difference in the vascular responses to estrogen may occur between 
human and animals, various experiments were conducted on the volunteers to clarify 
whether the effect of estrogen on the human is similar to that in the experimental 
animals. In experiments investigating the acute effect of estrogen, it was found that 
intra-arterial infusion of physiological levels of 17(3-estradiol selectively potentiated 
the endothelium-dependent vasodilator response to acetylcholine in the healthy 
postmenopausal women (Gilligan et al, 1994). Moreover, a significant decrease in 
cardiac output and heart rate was observed after estrogen administration (Hayward et 
al” 2000; Luotola et al” 1979). In addition, it was reported that the 
endothelium-dependent responses to intracoronary 17p-estradiol improved in 
post-menopausal women, but not in men with coronary atherosclerosis (Collins et al., 
1995)，indicating that acute estrogen administration appears to benefit the 
cardiovascular system of postmenopausal women only. 
Other experiments were carried out to examine the chronic effect of estrogen. 
Estrogen replacement therapy increased plasma N O levels and decreased plasma 
endothelin-1 levels (Wilcox et al., 1997). Moreover, the flow-mediated dilation of the 
brachial artery increased with the rise in plasma estrogen during the mid-cycle 
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follicular stage during the ovarian cycle (Hashimoto et al., 1995), indicating that 
endogenous estrogen affects the vasomotor activity. In addition, an increased level of 
bradykinin and a concomitant decrease of plasma angiotensin converting enzyme 
activity were observed after hormone replacement therapy (Sumino et al., 1999). 
Furthermore, it is found that postmenopausal estrogen replacement therapy raised H D L 
cholesterol and lower total and LDL cholesterol (Godsland, 2001). These findings are 
comparable with the results obtained in animal studies, suggesting that the vascular 
effect of estrogen is quite similar between human and experimented animals. 
1.6. Therapeutic Values of Estrogen and Progesterone 
Gender difference in the incidence of cardiovascular disease is well documented 
in literature. In the premenopausal reproductive years, women experience a lower risk 
of coronary heart disease (CHD) compared with men with the same age. After 
menopause, this difference significantly narrows unless estrogen replacement therapy 
is initiated. The epidemiological study demonstrates that the postmenopausal women 
receiving estrogen therapy have a much lower mortality rate in association with 
cardiovascular disease. Numerous studies suggested that current estrogen users have a 
risk of C H D about 50 % lower than that of nonusers, indicating the cardioprotective 
role of female sex steroid hormones. (Stampfer et al； 1991; Barrett-Connor & Bush, 
1991). 
Besides, estrogen is used to prevent the occurrence of osteoporosis. It was reported 
that long-term administration of mestranol (estrogen analogue) prevented bone loss and 
height loss when comparing with the placebo group (Lindsay et al, 1976; Lindsay et al, 
1980). 
Moreover, it was found that the age-specific incidence rate of Alzheimer's disease 
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is nearly twice as high in women as in men (Henderson & Buckwalter，1994). It is 
therefore proposed that the estrogen deficiency associated with menopause may 
contribute to the higher incidence of Alzhemier's disease in women. 
Although estrogen replacement therapy reduces the risk of coronary heart diseases, 
some side effects were reported. Endometrial cancer incidence increased rapidly with 
use of estrogen treatment (Zeil & Finkle，1975), however, breast cancer incidence 
increased only after long-duration use of estrogen (Colditz et al., 1995). Therefore, 
efforts have been made to reduce this disadvantage by adding progesterone in the 
therapy，so called hormone replacement therapy. Some literatures described that the 
incidence of endometrial cancer was reduced by addition of progesterone (The Writing 
Group for the PEPI Trial, 1995). 
On the other hand, estrogen and progesterone are used for birth control. Oral 
contraceptives contain synthetic estrogen and progestin, which suppress ovulation 
primarily through inhibition of the hypothalamic-pituitary-ovarian feedback system. In 
addition, these hormones throughout the cycle create suboptimal endometrial 
development, as a result, the endometrium would not be suitable for implantation 
(Pharmaceutical Society of Australia, 1998). 
In summary, female steroid hormones have many actions on endothelial cells, 
vascular smooth muscle cells, osteoblasts, neurons and many other cells. Although 
administration with such hormones causes some adverse effects, they are still 
commonly used in hormone replacement therapy for postmenopausal women who 
experience increasing incidence of cardiovascular disorder. 
« 
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1.7. Objectives of the Present Study 
Cardiovascular disease is rare in premenopausal women compared with men in 
similar age groups. However, the gender difference in cardiovascular disorder 
diminishes, and there is an increased incidence of cardiovascular risk in 
postmenopausal women. Although a number of factors contribute to the development 
of atherosclerosis, hypertension and coronary heard disease in women, estrogen 
replacement therapy reduces cardiovascular risk. Some cellular mechanisms have been 
investigated both in vivo and in vitro. Cardiovascular benefiting effects of estrogen 
include anti-hypertensive, hypocholesterolemic, anti-proliferaive and inhibition of 
oxidation of LDL. Figure 5 summarizes the published cellular and ionic mechanisms by 
which estrogen exerts its vasodilator effect. Estrogen can target both endothelium and 
the adjacent vascular smooth muscle cells to reduce the force of contraction. However, 
many questions remain to be answered in cardiovascular pharmacology of female sex 
steroid hormones. Therefore, I proposed the following four major objectives in my 
、 thesis work: 
1. To investigate the differential role of endothelium and endothelium-derived 
relaxing factors in the relaxant response to 17P-estradiol and progesterone in 
isolated rat aortas and mesenteric arteries. 
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2. To investigate the synergistic interaction between 17(3-estradiol and 
P-adrenoceptor agonists of low concentrations and to examine the possible 
cellular mechanisms responsible for this synergistic action in isolated rat 
mesenteric arteries. 
3. To investigate the possible enhancing effect of physiological concentration of 
17P-estradiol following acute exposure on P-adrenoceptor agonist-induced 
vasorelaxation in isolated porcine coronary arteries. 
4. To investigate the influence of chronic 17p-estradioI deprivation on vascular 
reactivity in the isolated common carotid arteries in ovariectomized rats. 
All experiments were designed to examine the unexplored effect of female sex 
steroid hormones in blood vessels. This study should provide some new findings and 
information regarding pharmacology of 17p-estradiol and progesterone. A long-term 
impact of this work remains to be confirmed. 
� 
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Figure 5 
The proposed mechanisms involved in the 17P-estradiol-induced relaxant response in 
blood vessels, p-adrenoceptor agonists, such as isoproterenol and fenoterol may 
enhance the 17p-estradiol relaxation. AC, adenylate cyclase; ATP, adenosine 
triphosphate; P-AR, (3-adrenocepter; cAMP, cyclic adenosine monophosphate; cGMP, 
cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; ER, 
estrogen receptor; GC, guanylate cyclase; GTP, guanosine triphosphate; L-Arg, 
L-arginine; L-NAME, N^-Nitro-L-Arginine methyl ester; M B , methylene blue; PKA, 
cAMP-dependent protein kinase; PKG, cGMP-dependent protein kinase; VOCC, 
voltage-operated Ca^^ channels. 
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Chapter 2 Methods and Materials 
2.1. Tissue Preparation 
2.1丄 Preparation of the rat aorta, mesenteric artery and carotid artery 
Male or female Sprague-Dawley rats of body weight about 300-350 g (supplied by 
Animal Services Center, The Chinese University of Hong Kong, Hong Kong) were 
used in this study. They were killed by pure carbon dioxide. The rat thoracic aorta, 
mesenteric artery or carotid artery were dissected out and subsequently placed into 
freshly prepared and oxygenated Krebs-Henseleit solution. Under a light microscope, 
the surrounding adipose and connective tissues were carefully removed. Each vessel 
was then cut into ring segments of approximately 4-mm in length for the aorta and 
3-mm in length for the mesenteric artery or carotid artery. Three to four rings of 
thoracic aorta and mesenteric artery, either with endothelium or without endothelium, 
were prepared from each rat for recording of isometric tension. Each experiment was 
performed on arterial rings prepared from different rats. All experiments described in 
this thesis were approved by the Animal Research Ethics Committee, The Chinese 
University of Hong Kong. 
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2.1,2. Removal of the functional endothelium 
In some experiments, the endothelial layer was mechanically disrupted by gently 
rubbing the luminal surface of an arterial ring back and forth several times with a plastic 
tube or small stainless steel wire. Successful removal of the functional endothelium was 
confirmed by the absence of a relaxant response to acetylcholine (0.1 |iM for the aorta, 
0.3 |iM for the mesenteric artery or carotid artery), an endothelium-dependent 
vasodilator (Furchgott and Zawadzki, 1980). Endothelium integrity or denudation was 
also evaluated by light microscopy of the histological section of an artery. 
2.2. Organ Bath Set-up 
After vessel preparation, each arterial ring was mounted between two stainless 
steel wires (100 |am in diameter) submerged in an organ bath. One of the steel wires was 
fixed to a built-in support at the bottom of the organ bath, while other was connected to 
a force-displacement transducer (FT-03, Grass Instruments Co., Quincy, M A , USA). 
Changes in isometric force were continuously recorded, and either displayed on a chart 
recorder or stored by a Maclab software (version 3.5). The diagram in Figure 6 
illustrates a set-up for measurement of force of contraction. 
Each ring was kept in、a 10-ml organ bath containing freshly prepared 
Krebs-Henseleit solution. The temperature of the bathing solution was maintained at 
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Figure 6 
• Diagrammatic illustration of isometric force measurement. An artery ring was mounted 
in an organ bath and changes in contractile force were detected by a Grass force 
transducer. 
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37。C by a heating pump (Polyscience, USA) connected to a circular heat exchanger. 
The temperature was continuously monitored with a miniature thermometer probe 
(Edale Instruments Ltd., Cambridge, England). The bath solution was gassed 
continuously with a mixture of 95% O2 and 5% CO2 to give a pH of 7.3-7.4. All 
solution changes were done through the outlet of the organ bath to a waste container 
and replacement with a solution pre-warmed to the same temperature. 
Arterial rings were suspended optimally under an initial passive resting tension 
of 1 g for aorta and 0.5 g for mesenteric arteries and carotid arteries. Rings were 
allowed to equilibrate for about 60 minutes. Within this period of time, the bath solution 
was replaced with oxygenated and pre-warmed Krebs solution every 20 minutes. The 
resting tension was readjusted to the optimal resting level, if necessary following each 
replacement of bath solution. 
2.3. Force Measurement 
After 60-minute equilibrium, each ring was first contracted with a single 
concentration of phenylephrine (0.3 jiM for aorta and 3 |iM for mesenteric arteries or 
carotid arteries in the presence of endothelium) to test the contractility. Removal of the 
V 
endothelium was verified by lack of the relaxant response to acetylcholine (0.3 |iM for 
aorta and 1 ^iM for mesenteric arteries or carotid arteries). Only those 
-Page 28 -
Estroeen and Vascular Contractility / HY Chan 
endothelium-intact rings that were relaxed over 85% by acetylcholine were chosen for 
the present study. Thereafter, the rings were washed several times with Krebs-Henseleit 
solution until muscle tension returned to the basal tension. 
Vascular action of 17 (i-estradiol and progesterone 
Role of endothelial nitric oxide in 17p-estradioU or progesterone-induced 
relaxation 
In this group of experiments, both endothelium-intact and denuded rings were 
allowed to stabilize for additional 60 minutes under respective resting tension. The 
rings were contracted by phenylephrine at different concentrations in order to generate 
muscle tone of similar magnitude in endothelium-intact and -denuded rings (in 
mesenteric artery: 3 |iM with endothelium and 1 |iM without endothelium; in aorta: 0.3 
^iM with endothelium and 0.1 |jM without endothelium). After sustained tension 
80% of the maximal contractile response to phenylephrine) was obtained, 17(3-estradiol 
or progesterone was added cumulatively to the bath solution. In experiments testing the 
role of endothelial nitric oxide, rings were exposed for 30 minutes to each of nitric 
oxide activity inhibitors (N^-nitro-L-arginine methyl ester and methylene blue) prior to 
V 
application of phenylephrine： In some experiments, the endothelium-intact rings were 
first treated with 1 m M L-arginine for 10 minutes, then with 30 fiM N^-nitro-L-arginine 
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methyl ester before addition of phenylephrine. Since nitric oxide inhibitors enhanced 
phenylephrine-induced tone, the concentration of phenylephrine was lowered to 0.1 
fiM for the aortas and 1 fiM for the mesenteric arteries. 
2.3丄2. Role of inducible nitric oxide in progesterone-induced relaxation 
Apart from the role of endothelial nitric oxide, I also examined the role of 
inducible nitric oxide in progesterone-induced relaxation. Either endothelium-intact 
or -denuded mesenteric arteries were exposed for 30 minutes to A M T HCl (5-30 nM). 
The rings were contracted by 9,11 -dieoxy-11 a,9a-epoxymethanoprostaglandin F2« 
(U46619) at 30 n M with endothelium or at 10 n M without endothelium in order to 
generate similar vessel tone. After a sustain contraction, progesterone (0.03-300 |iM) 
was applied cumulatively to induce a concentration-dependent response. 
2.3.入 Effect of estrogen receptor inhibitor on 17^estradiol-induced relaxation 
After testing the presence of endothelium, the endothelium-intact mesenteric 
artery rings were exposed for 30 minutes to ICI 182,780 (1-10 _ before addition of 
phenylephrine (3 pM). Once sustain contraction was obtained, 17p-estradiol (0.3-300 
� 
fiM) was applied cumulatively to the bath solution. 
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2.3.1.4. Interaction between progesterone and 17^estradiol 
In this set of experiments, the endothelium-intact mesenteric arteries were 
incubated with progesterone (0.3-1 |nM) for 2.5 hours. After this period of time, the 
rings were contracted by U46619 (30 nM). After the contractile response reached a 
steady level, 17p-estradioI (0.03-300 fiM) was added cumulatively to obtain 
concentration-response curves. 
2.3丄5. Effect of 17^estradiol on protein kinase C-mediated contraction 
In order to gain information on whether 17p-estradiol may interfere with 
Ca2+-independent contractile mechanisms such as activation of protein kinase C in 
vascular smooth muscle cells, the effect of 17p-estradiol was examined on phorbol 
12,13-diacetate (PDA)-induced sustained increase of muscle tension. 
In this set of experiments, the endothelium-denuded mesenteric artery rings were 
first incubated for 20 minutes in Ca^ -^free solution containing 0.3 m M Na2-EGTA and 
washed with the same solution twice before addition of 1 |iiM PDA, the protein kinase 
activator. Once a sustained tension was obtained, 17P-estradiol or progesterone was 
added cumulatively (0.1-300 |LIM) to the bath. In some experiments, the similar 
procedure was repeated in normal Ca^ '^ -containing Krebs solution. 
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2 3.1.6. Synergistic interaction between ^-adrenoceptor agonists and 17p-estradiol 
Relaxations induced by 17|3-estradiol were studied in rat isolated mesenteric artery 
rings contracted by U46619, the concentration of which (10-30 nM) was titrated for each 
vessel to give a contraction of similar magnitude. When stable tone was obtained, 
17p-estradiol was applied cumulatively (0.1 - 100 |iM) to the bath solution to determine 
concentration-response relationships. To examine the potential modulation by 
P-adrenoceptor activation of 17P-estradiol-induced relaxation, the 
concentration-dependent relaxing effects for (3-adrenoceptor agonists were determined. 
The concentration that caused approximately 0-10% the maximal relaxation was used. In 
the first series of experiments, the vessels were exposed to isoproterenol for 1 hr before 
addition of U46619. In some experiments, the rings were incubated with the Pi- or 
p2-adrenoceptor antagonist for 10 minutes before addition of p-adrenoceptor agonist. 
Some experiments was designed to examine the possible involvement of 
endothelium-derived relaxing factor (nitric oxide), the effect of isoproterenol was 
investigated in endothelium-intact rings pretreated with N^-nitro-L-arginine methyl ester 
(an inhibitor of nitric oxide synthase) or in endothelium-denuded rings. In the last set of 
experiments, the endothelium-intact rings were exposed to Rp-cAMPS triethylamine (an 
inhibitor of cyclic AMP-dependent protein kinase) or Rp8-pCRT-cGMPS triethylamine 
(an inhibitor of cyclic GMP-dependent protein kinase la) for 10 minutes before addition 
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of isoproterenol. All experiments were carried out in the presence of 10 |iM indomethacin 
to exclude contribution of prostanoids. 
2.4. Porcine Coronary Artery Experiments 
2.4.1. Vessel preparation 
Coronary arteries were obtained from porcine hearts that were harvested in a local 
slaughterhouse in Hong Kong. Immediately after the pig was killed, the heart was 
rapidly removed, placed in a container filled with oxygenated Krebs-Henseleit solution 
at 4 and transferred to the laboratory. Epicardial left circumflex coronary arteries 
were dissected free of surrounding connective tissues, cut into 3-mm-long rings, and 
mounted on a pair of stainless steel wires in organ bath (see Section 2.2) filled with 
Krebs solution at 37 °C. 
2.4.2. Force measurement 
After 1-hr equilibration, the rings were first contracted with a single concentration 
of U46619 (3 nM). Removal of the endothelium was verified by the lack of relaxant 
response to bradykinin (50 nM). In contrast, bradykinin relaxed by over 85% 
U46619-precontracted arteries, indicating the presence of the functional endothelium. 
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Thereafter, the rings were washed several times with Krebs-Henseleit solution until 
muscle tension returned to the basal tension of 2 gram. 
2.4.3. Experimental protocol 
2.4.3.1. Effect of physiological level of 17(^-estradiol on ^adrenoceptor 
agonist-induced relaxation 
The rings of endothelium-intact porcine coronary arteries were first exposure to 
physiological concentrations of ivp-estradiol (0.1-1 nM) for either 20 minutes or 1 
hour. The rings were then contracted with U46619 (3 nM) to establish a sustained 
contraction. After the contraction had reached a steady level, each of three 
P-adrenoceptor agonists: isoproterenol, fenoterol or dobutamine was applied to the 
organ bath cumulatively to induce concentration-dependent responses. 
In some experiments, the inhibitory effect of tamoxifen was investigated. 10 |LLM 
tamoxifen was added 10 minutes prior to application of 17p-estradiol. Then the 
protocol was similar to the above to obtain concentration-response curve. 
2.4.3.2. Effect of physiological level of 17^estradiol on phosphodiesterase 
inhibitor-induced relaxation 
� 
The endothelium-intact porcine coronary artery rings were first exposed to 
17p-estradiol (0.1-1 nM) for either 20 minutes or 1 hour. They were then contracted 
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with U46619 (3 nM). After the contractile response reached a steady level, 
3-isobutyl-l-methylxathine (IBMX) (0.01-300 |iM) was applied to the organ bath 
cumulatively to induce concentration-dependent responses. 
2.5. Ovariectomy 
2,5,1. Method of ovariectomy 
Menopause was induced surgically in female Sprague-Dawley rats by bilateral 
ovariectomy. About fifty rats (200-250 g), aged between 3 and 4 weeks, were 
anesthetized intraperitoneally with 2.5% sodium pentobarbitol (0.16 ml/100 g). The 
ovaries were ligated and then removed. Following surgical operation, rats were then 
allowed to recover for 14 days with food and water，and were kept in a 12:12-hr 
light/dark cycle. At day 15, 17p-estradiol-impregnated timed-released pellets (0.5 
mg/pellet; 21-day release, Innovative Research of America) were implanted 
subcutaneously in the estrogen-replaced group (n=10). The second group of rats (n=10) 
underwent ovariectomy but received no estrogen replacement. Tamoxifen citrate 
time-released pellets (0.5 mg/pellet; 21-day release, Innovative Research of America) 
were implanted subcutaneously in the third group (n=10). In the forth group (n=10), the 
rats were implanted with both of 17p-estradiol and tamoxifen pellets. These four 
groups of rats were kept under the same conditions together with a sham-operated 
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group (or control group) (n=10) (Figure 7). Tail-cuff systolic pressure and heart rate 
were measured every week and body weight was simultaneously recorded. The rats 
were killed by cervical dislocation three weeks after the pellet implantation. The serum 
for (3-estradiol level was obtained by collection of trunk blood the blood from 
abdominal aorta followed by centrifugation. The weights of the uterus were also 
recorded. The plasma estradiol levels were determined by an ELIS A. 
2,5,2, Preparation of blood vessels 
The rats were killed by cervical dislocation and the common carotid arteries from 
both sides were dissected out under a sterile condition, and placed in Krebs-Henseleit 
solution that had been bubbled with a gas mixture of 95% O2 plus 5% CO2. Each artery 
was cleaned off the surrounding connective tissues, and then cut into ring segments of 
approximately 3-mm in length. In some experiments, the endothelium layer was 
mechanically disrupted by gently rubbing the luminal surface of an arterial ring back 
and forth several times with plastic tubing. The removal of endothelium was verified by 
failure of rings to relax in response to acetylcholine. All rings were equilibrated for 60 
minutes before the experiment commenced. 
V 
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Sham -
Placebo \ 
\ 2 weeks 
\ 
^ ^ ^ ^ 17p-E,peUet \ 
1) Weight ^ ^ ^ 
2) Blood pressure 广 X Tamoxifen 
3) Serum E, level ^ ^ ^ ^ — ^ ^ ^ ^ 
4) Isometric tension —^ 
measurement 
5) RNA extraction & x^c^ ITp-E：】+ 
semi-quantitative ^^^^^g^Qv^^^^^^^amoxifen pellet 
RT-PCR 
Figure 7 
Diagrammatic illustration of ovariectomy experiments. There are five groups: Control, 
ovariectomized, estrogen-replaced, tamoxifen-replaced, co-treatment of estrogen and 
tamoxifen group. 17p-E2, 17p-estradiol. 
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2.5.3. Experimental protocols 
2.5.3.1. Effect of ovariectomy on contractility of rat carotid arteries 
Following the equilibration period, both endothelium-intact and -denuded carotid 
arteries were contracted by adding phenylephrine (0.001-10 [lM) and U46619 (1-50 
nM) cumulatively. Endothelium-denuded arteries were contracted by high extracellular 
K+ (5-80 m M ) cumulatively. All the results were expressed in term of actual force 
(mN). 
2-5.3.2. Effect of ovariectomy on relaxation properties of rat carotid arteries 
After 60-min equilibration period, the endothelium-intact carotid arteries were 
contracted by 30 n M U46619. Once the sustained tension was reached, acetylcholine 
was added cumulatively (0.001-30 pM) to induce concentration-dependent relaxation. 
� 
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2.6. Chemicals and Solutions 
Table 2 contains a list of chemicals and drugs used in the present study. They were 
purchased from Sigma (Sigma Chemicals, St. Louis, M O , USA), RBI (Research 
Biochemicals International, Natick, M A , USA), Tocris (Tocris Cookson Ltd., Bristol, 
UK). The chemical safety for using these compounds was approved by the Safety 
Office, The Chinese University of Hong Kong, Hong Kong. 
Table 2 Chemicals and drugs 
Chemicals Description Solvent Source 
np-estradiol pellet 17p-estradiol-impregnated Innovative 
time-released pellet (0.5 mg/pellet; 一 Research 
21-day release) of America 
3-Isobutyl-1 - Potent phosphodiesterase inhibitor; D M S O Sigma 
methylxathine more active than theophylline at  
adenosine receptors 
9,ll-Dideoxy-lla,9a- Thromboxane A2 analogue D M S O Sigma 
epoxymethano- vasoconstrictor 
prostaglandin F2a 
(±)-Atenolol Selective pi-adrenoceptor D M S O  
antagonist  
Acetylcholine Muscarinic receptor agonist; H ^ Sigmsi 
Endothelium-dependent vasodilator 
A M T HCl Potent, selective and reversible RoO 
inhibitor of inducible nitric oxide  
synthase  
Bradykinin Neuropeptide which contracts H ^ j^gj 





increase capillary permeability 
(3-estradiol Estrogen, sex hormone ~ D M S O 
Dobutamine pi-adrenoceptor agonist H ^ T b ^ 
hydrochloride  
Fenoterol Pi-adrenoceptor agonist H ^ S i g m a ~ 
hydrobromide  
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Forskolin Adenylate cyclase activator D M S O RBI 
ICI 118,551 Selective Pz-adrenoceptor H ^ m 
antagonist  
ICI 182, 780 Estrogen receptor antagonist Tocris — RBI 
(±)-Isoproterenol HCl Non-selective p-adrenoceptors H ^ 
agonist  
L-Arginine Nitric oxide precursor H2O — Sigma 
Methylene blue Inhibitor of guanylate cyclase H2O Sigma 
N -nitro-L-arginine Competitive inhibitor of nitric H^ RBI 
methyl ester oxide synthase 
hydrochloride  
Phenylephrine HCl ai-adrenoceptor agonist, H ^  
vasoconstrictor  
Progesterone Female sex steroid hormone D M S O ~ ^ 
DL- Propranolol Non-selective P-adrenoceptor D M S O S i ^ 
antagonist  
Phorbol Protein kinase C activator, D M S O 
12,13-diacetate vasoconstrictor  
Rp-cAMPS Specific inhibitor of H ^ s i ^ 
triethylamine cAMP-dependent protein kinase I 
andn  
Rp-8-pCRT-cGMPs Inhibitor of cGMPs-dependent H ^ ^ 
triethylamine protein kinase la  
Sodium pentobarbitol Anesthetic h ^ sigma “ 
Tamoxifen citrate Anti-estrogen d M S O R B I 
Tamoxifen pellet Tamoxifen citrate time-released Innovative 
pellets (0.5 mg/pellet; 21-day 一 Research  
releaseO of America 
The drug stock solution was normally prepared and stored in distilled water or 
D M S O . Further dilution was made when necessary, in distilled water or D M S O to a 
desired concentration, p-estradiol, fenoterol hydrobromide, (±)-isoproterenol HCl, 
methylene blue, phorbol 12’ 13-diacetate are light-sensitive, the stock solution was 
protected from light stimulation. 
• Table 3 contains compositions of three different solutions used in my study. They 
were freshly prepared before the experiments. 
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Table 3 Compositions of Solutions 
Krebs-Henseleit Ca'^ free 60 mM K+ ^^ 
( _ (mM) (mM) /二枕  
(mM) 
^ n9 119 « S  
NaHCOs 25 25 25 25 
MgClr 6H2O 1 1 1 1 
KCl 4.7 4.7 60 60 
KH2PO4 1.2 1.2 1.2 12 
CaCl2 2.5 0 2.5 0 
D-glucose 11.1 11.1 11.1 11 1 
Na2-EGTA 一 0.3 一 — 
I 
The pH value of normal Krebs, Ca^ "" free and 60 m M K+ solutions was maintained 
at 7.3-7.4 when the bath solution was continuously oxygenated with a mixture of 95% 
O2 plus 5% CO2 at 37 ° C 
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2.7. Statistical Analysis 
Data are presented as means 土 standard errors of the mean (S.E.M.) and n refers to 
the number of arterial rings (animals) examined. The relaxant responses to 
17p-estradiol or progesterone are expressed as percentage reversal of the 
vasoconstrictor-induced contraction. In Section 3.1. to 3.4.，IC50 values were calculated 
as the drug concentration causing the half maximum relaxation. These values were 
compared in the absence and presence of various pharmacological agents. Cumulative 
concentration-relaxation relations were analyzed with non-linear curve fitting by 
means of a logistic equation (Grafit, Erithacus Software Ltd.). In Section 3.5.-3.7., the 
negative logarithm (-log) of the concentration of a drug required to produce 50% (pD!) 
the maximal relaxation was calculated by non-linear regression curve fitting (Graphpad 
Prism Software, version 3.0’ USA). Statistical analysis was performed by using 
Student's t-test (two-tailed) or one-way analysis of variance (ANOVA) followed by 
Newman-Keuls test when more than two groups were compared. A P value < 0.05 was 
taken to indicate a significant difference. 
� 
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Chapter 3 Results 
3.1. Role of Endothelium/Nitric Oxide in 17p-Estradiol- and 
Progesterone-induced Relaxations 
3丄 J. Relaxant response of 17j^-estradiol 
As shown in Figure 8，1 |iM 17p-estradiol caused approximately 20% 
relaxation in an isolated endothelium-intact aorta (Figure 8a), but not in an 
endothelium-denuded aortic ring (Figure 8b). In the phenylephrine-contracted isolated 
rat endothelium-intact aortas, np-estradiol induced concentration-dependent 
relaxations with an IC50 of 2.28 士 0.14 |iM (n=8). Removal of the functional 
endothelium significantly reduced the relaxing potency of 17p-estradiol with an IC50： 
8.13 土 0.51 m M (n=6, P < 0.05 compared with that obtained with endothelium). 
Figure 9a shows that the concentration-response curve for IVP-estradiol-induced 
relaxation was shifted to the right in the endothelium-denuded aortas. However, the 
results are different in the isolated rat mesenteric arteries. 17p-estradiol also 
concentration dependently decreased the phenylephrine-induced tone in rat mesenteric 
artery rings, but this relaxant response was unrelated to the presence of endothelium. 
The IC50 values are 6.37 ± 1.4 ^ iM (n=5) and 5.29 土 0.79 ^ lM (n=4) for the relaxant 
effect of np-estradiol in rings with and without endothelium, respectively (P > 0.05， 
Figure 9b). A similar magnitude of vessel tone was produced by titrating 
phenylephrine concentration in both endothelium-intact and -denuded rings. 
� 
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17p-Estradiol (jiiM) 
a. —   
I 3 
J ^ 1 
1 10 mm 
Phe 0.3 |liM 
b. i l l 
I 4mN I_ 100 
10 min 
个 
Phe 0.1 _ 
Figure 8 
The concentration-dependent relaxations induced by 17(3-estradiol in phenylephrine-
contracted rat aortic rings with endothelium (a) and without endothelium (b). 
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� Aorta 
a . -1 
1 0 0 : • +Endo , J t ^ • 
g 8 0 - - Endo / / 
I 6 0 - Y I 
^ 40- 厂 
承 2 0 : y / 
0 
‘~I I I Mii| II I 11 iii| 1I I 11 丨||| 1~~ri 
0.1 1 10 100 
17B-Estradiol (|liM) 
b Mesenteric artery 
g ^ +Endo 
•运 8 0 - + - Endo F 
M 60-
0 — f ^ - ^ - - - 
‘ • ‘ I …|| I I I …111 1 I I I iiii| r-r-i 
0.1 1 10 100 
17B-Estradiol (|UM) 
Figure 9 
Concentration-response curves for the relaxant response to 17p-estradiol in the rat 
.aortas (a:〇，n=8 with endothelium;眷，n=6 without endothelium) or in the 
^senteric arteries (b:〇，n=5 with endothelium; •’ n=4 without endothelium) The 
data are means ± S.EM, of n experiment. A significant difference between text and 
control values is indicated by asterisk* (P < 0.05). 
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3.1.2. Effects of inhibitors of nitric oxide activity on 17 f3-estradiol-
induced relaxation 
The concentration-dependent relaxant effect of 17~-estradiol (Figure 9a) was 
significantly greater in the endothelium-intact than endothelium-denuded aortas, 
indicating that the endothelium-derived vasoactive factors are involved. 
Pretreatment of endothelium-intact aortic rings with 30 ~ NG-nitro-L-
arginine methyl ester (L-NAME) inhibited 17~-estradiol-induced relaxation, while 1 
mM L-arginine reversed the effect of L-NAME (Figure lOa). Mo.reover, pretreatment 
of methylene blue (1 0 ~M) which is an inhibitor of guanylate cyclase, also 
significantly attenuated the 17~-estradiol-induced relaxation to the same degree as 
that seen with L-NAME in Figure lOa (Figure lOb). These data favour a role of 
endothelium/nitric oxide in the 17~-estradiol-induced relaxation in the rat aortas. 
3.1.3. Relaxant response ofprogesterone 
The concentration-dependent relaxant effect of progesterone was significantly 
greater in an endothelium-intact (Figure 11 a) than endothelium-denuded mesenteric 
artery (Figure lIb), indicating that the endothelium-derived vasoactive factors may be 
involved. Figure 12b shown that progesterone induced relaxation with greater 
effectiveness in endothelium-intact mesenteric artery rings than endothelium-denuded 
rings. The ICso values are 2.63 ± 0.48 ~M (n=9) and 8.58 ± 1.17 ~M (n=6) for the 
relaxant effect of 17~-estradiol in mesenteric arteries with and without endothelium, 
respectively (P < 0.05). However, this endothelium-dependent effect was not 
. observed in the rat aortas. Progesterone relaxed the phenylephrine-preconstricted 
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17B-Estradiol (~) 
Figure 10 
Ca) Concentration-response curves for 17p-estradiol-induced relaxation in rat 
endothelium-intact aortas (0, n=9-for control~ e, n=5 for 30 /lM L-NAME~ 0, n=4 
for 1 mM L-arginine plus 30 /lM L-NAME). (b) Concentration-response curves for 
. 17B-estradiol in rat endothelium-intact aortas (0, n=9 for control~ e, n=5 for 3 /lM 
MB~ ., n=5 for 10 /lM MB). The data are means ± S.E.M. of n experiments . A 
significant difference between text and control values is indicated by asterisk* (P < 
0.05). 
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Figure 11 � 
• The concentration-dependent relaxations induced by progesterone in phenylephrine-
contracted rat aortic rings with endothelium (a) and without endothelium (b). 
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Progesterone (JlM) 
Concentration-response curves for progesterone-induced relaxation in rat aortas (a) 
and mesenteric arteries (b) with endothelium (0 , n=7-9) and without endothelium (e, 
. n=6-10). The data are means ± S.E.M. of n experiments . A significant difference 
between text and control values is indicated by asterisk* (P < 0.05) . 
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endothelium-intact aortas with an ICso of 6.35 ± 0.77 J-lM (n=7), and this value was 
similar to that obtained in endothelium-denuded rings (ICso: 6.68 ± 0.85 J-lM, n= 1 0, P 
> 0.05) (Figure 12a). 
3.1.4. Effects of inhibitors of nitric oxide activity on progesterone-
induced relaxation 
Progesterone-induced relaxation in endothelium-intact mesenteric artery rings 
was significantly attenuated by pretreatment with 30 and 1 00 J-l~ L-NAME (Figure 
13a). L-arginine at 1 mM partially reversed the inhibitory effect of 30 J-lM L-NAME 
on progesterone-induced relaxation (Figure 13a). In addition, pretreatment with 3 IlM 
methylene blue also caused rightward shift of the concentration-response curve for 
progesterone-induced relaxation (Figure 13b). The percentage relaxation induced by 
acetylcholine and initial vessel tension are presented in Table 4 and the ICso values 
from Figure 8-13 were summarized in Table 5. 
In addition, the effect of AMT HCI, an inhibitor of inducible nitric oxide 
synthase, was also examined: In this series of experiments, pretreatment of rings with 
AMT HCI at three concentrations (5, 10 and 30 nM) inhibited the progesterone-
induced relaxation in rat endothelium-intact mesenteric arteries (Figure 14a), 
indicating that 30 nM is the concentration at which AMT HCI maximally inhibited the 
progesterone-induced relaxation. However, exposure of endothelium-denuded rings to 
the same concentrations (5-30 nM) of AMT HCI did not cause shifts of the 
concentration-response curve (Figure 14b). AMT HCI at 30 nM slightly enhanced 
progesterone-induced relaxation (Figure 14b). The ICso values from Figure 14 were 
summarized in Table 6. 
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Figure 13 
(a) Concentration-response curves for progesterone-induced relaxation in the rat 
m a ^ T'^T.' mesenteric arteries (〇，n=9 for control; n=8 for 30 u M L-
for 1 m M L-arginine plus 30 _ L-NAME; •，n=5 for 100 _ L-
• N f E) (b) Concentration-response curves for progesterone-induced relaxation in rat 
endothelium-intact mesenteric arteries (〇，n=9 for control;眷，n=5 for 3 u M M B ) 
Jhe dat，are means ± S.E.M of n experiments. A significant difference between text 
and control values is indicated by asterisk* (P < 0.05). 
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Igfeki Acetylcholine4nduced relaxation and phenylephrine-induced 
in應 t霞 of endothelium-intact rings in different treatment 
groups 
17P-Estradiol in aortas Progesterone in mesenteric arteries 
Groups“Relaxation MiaLtone Rdaxation hid^jl^  
幽 ^ ~ (mN) -
Control 78.3 ±10.0 15.1 土 0.9 8 92.0 土 3.0 8.1 土 1.1 9 
L-NAME 
30 _ 76.3 ±4.1 17.7 ± 1.4 5 84.1 ±9.8 8.2 ±0.6 8 
L-NAME 
100 jiM 90.7 ±4.8 7.6 ±0.9 5 
L-Arg 
+ 80.4 ±5.3 16.1 ±1.3 4 94.6 ±3.2 8.6±07 6 
L-NAME 
M B 3 _ 79.3 ±3.8 14.3 土 2.8 5 88.8 土 1.8 8.5 ±0.6 5 
M B 10 m m 75.1 土 2.6 16.8 ±0.9 5   
Acetylcholine-induced relaxation in phenylephrine-preconstricted rings was taken as 
an index of the presence of the functional endothelium and this value was not 
different among various treatment groups. Following confirmation of the integrity of 
endothelium, the initial tone induced by phenylephrine (0.1-3 ^ M) was similar amon. 
different groups. Statistical analysis was performed using one-way A N O V A followed 
by Student-Newman-Keuls test. 
� 
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T^tS Effects of nitric oxide inhibitors on relaxation induced by 17> 
estradiol and progesterone 
1加 C 务 J- , • Progesterone in 
17p-Estradiol in aortas 
mesenteric arteries 
ICsoiuMl n ICso n 
+Enclothelium 
Control 2.28 ±0.14 8 2.63 ±0.48 9 
L-NAME 30|LIM 6.94±0.36& 5 7.54 士 0.7ia g 
L-NAME 100 |jM 一 12.3 ± 1 5 
L-Arginine 1 m M + 
L-NAME 30 m m 3.37±0.19b 4 4.02 ±0.90^ 6 
M B 3 |LIM 4.80 ± 0.27a 5 6.64±0.72& 5 
M B 10|LIM 7.83 ± 0.73A 5 一 
-Endothelium 8.13±0.51& 6 8.58 ± 1.17a 6 
IQo values for the relaxant response to 17P-estradiol in the isolated rat aortas and to 
progesterone in the mesenteric artery rings. Statistical difference (P < 0.05) was 
indicated between control and treatment groups O or between L-NAME group and 
L-Arg + L-NAME group ft. L-Arg, L-arginine; L-NAME, N^ -nitro-L-arginine 
methyl ester; MB, methylene blue. Results are means ± S.E.M. of ^  experiments. 
� 
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Figure 14 
The effects of A M T o n progesterone-induced relaxation in rat mesenteric arteries (a) 
wi，丄ndot巧um (〇，n=12 in control; •，n=6 in 5 n M A M T ; •，n=5 i: 二 7二 ? 
‘ 施 T) and (b) without endothelium (d, 0；7 in ontrof^T-^ 
Z L T . s T m oI in ⑴ 谨 ^ T and •’ n=5 in 30 n M AMI). Suit；； 
= i ： S 二 ; = 二 r ficant 一 between text and control 
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Table 6 Effect of AMT HCl on the relaxation induced by progesterone 
With endothelium Without endothelium 
I&oiuM) n ICsoiiMl n 
Control 3.62 ± 1.28 12 5.38 ±0.57 1 
5 n M A M T HCl 8.13 ±1.17* 6 4.81 土 0.52 6 
10 n M A M T HCl 10.89 土 1.02* 5 4.43 ±0.68 8 
30 n M A M T HCl 14.37 土 1.27* 6 2.68 ±0.5 5 
IC50 values for the relaxant responses to progesterone in the isolated rat mesenteric 
artery rings with and without the functional endothelium. Statistical difference 
between control and treatment groups is indicated by asterisk* (P < 0.05). Results are 
means 土 S.E.M. of n experiments. 
� 
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3.2. Effect of Estrogen Receptor Inhibitor on 17p-Estradiol-
induced Relaxation 
The presence of plasma membrane estrogen receptors was reported before 
(Pietras & Szego，1977), the effect of the estrogen receptor inhibitor was therefore 
investigated. In endothelium-intact mesenteric arteries, the concentration-response 
curve to 17p-estradiol was not affected by pretreatment with the estrogen receptor 
antagonist, ICI 182,780 (1-10 |LLM). The IC50 values are 4.79 土 0.07 |LIM for control; 
4.36 ± 0.11 )llM for 1 |iM; 3.29 土 0.03 |LiM for 3 fiM; 3.77 土 0.04 |iM for 10 |iM (P > 
0.05，Figure 15). 
3.3. Interaction between Progesterone and 17p-Estradiol 
The effect of progesterone was investigated in both rat endothelium-intact and 
endothelium-denuded mesenteric arteries. It was found that concentration-response 
curve for IVP-estradiol was shifted to the left when the endothelium-intact rings were 
pretreated for 2.5 hours with 0.3 or 1 | j M progesterone (Figure 16a). The IC50 values 
are 10.14 土 0.05 mM for control; 3.28 士 0.09 |liM for 0.3 |aM progesterone; 2.82 土 0.11 
M M for 1 |iM progesterone (P < 0.05, compared with the control value). However, 
progesterone did not affect 17p-estradiol-induced relaxation in endothelium-denuded 
tissues (Figure 16b). The IC50 values are 7.24 土 0.05 |iM for control and 5.82 土 0.04 jjM 
for 0.3 [M progesterone (P > 0.05，compared with the control value). 
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Figure 15 
The effect of ICI 182,780 on progesterone-induced relaxation in rat mesenteric arteries 
with endothelium (〇’ n=4 in control; n=5 in 1 |iM; •，n=3 in 3 _ and •, n=5 in 
10 pM). Results are means 土 S.E.M. of n experiments. ’ 
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Figure 16 
The effect of progesterone (P4) on the 17p-estradiol relaxation in rat mesenteric artery 
rings, (a) Concentration-response curves for ivp-estradiol in endothelium-intact tissue 
•(〇，N=7 for control;眷，N=6 for 0.3 |IM progesterone; •，N=6 for 1 |JM progesterone). 
(b) Concentration-response curves for 17p-estradiol in endothelium-denuded rings (〇， 
11=6 for control; •，n=8 for 0.3 _ progesterone). Results are means 土 S.E.M. of n 
experiments. 
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3.4. Effect of Female Sex Steroid Hormones on Protein 
Kinase C-mediated Contraction 
3.4丄 Effect of 17P-estradiol on phorbol ester-induced contraction 
In the phorbol 12，13-diacetate (PDA, 1 fiM)-contracted isolated rat 
endothelium-denuded mesenteric arteries, 17P-estradiol (0.1-300 |iM) induced 
concentration-dependent relaxations with an IC50 of 11.67 土 5.43 \iM (n=6) in normal 
Krebs solution. In the Ca^ '"-free Krebs solution, the relaxing potency of 17p-estradiol 
was enhanced with an IC50 of 3.41 土 0.4 |iM (n=6, P < 0.05). Figure 17 shows that the 
concentration-response curve for 17p-estradiol was shifted to the left when the 
experiments were repeated in Ca2+-free Krebs solution. The vessel tension induced by 
1 m M P D A was 11.3 土 0.5 m N and 10.7 土 0.6 m N in normal and Ca^ -^free Krebs 
solution, respectively. 
Effect of progesterone on phorbol ester-induced contraction 
In the isolated rat endothelium-denuded mesenteric arteries, progesterone (0.1-
300 jjM) induced concentration-dependent relaxations in the P D A (1 \xM)-
precontracted rings in either normal Krebs solution or Ca2+-free Krebs solution. 
Figure 18 shows that the relaxant effect of progesterone was greater in the Ca^^-free 
Krebs solution than in normal Krebs solution. The IC50 values are 24.97 土 0.84 |iM 
(n=7) and 14.64 土 2.6 |iM (n=9) in normal Krebs solution and Ca^ -^free Krebs 
solution，respectively (P < 0.05). The vessel tension induced by P D A is 9.8 土 0.6 m N 
and 11.7 土 0.4 m N in normal and Ca^ ''-free Krebs solution, respectively. 
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Figure 17 
The effect of extracellular Ca:.、on 17p-estradiol-induced relaxation in P D A 
contraction (〇，n=6 for nomial Krebs solution;眷，n=6 for Ca'^-free Krebs solution). 
The data are means 土 S.E.M. of n experiments. A significant difference between text 
and control values is indicated by asterisk* (P < 0.05). 
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Figure 18 
The effect of extracellular Ca:.、on progesterone-induced relaxation in P D A 
contraction (〇，n=7 for normal Krebs solution;眷，n=9 for Ca^^-free Krebs solution) 
The data are means 土 S.E.M. of n experiments. A significant difference between text 
and control values is indicated by asterisk* (P < 0.05). 
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3.5. Effects of P-adrenoceptor Agonists on 17P-Estradiol-
induced Relaxations 
3.5丄 Effect of isoproterenol on 17^estradiol-induced relaxation 
Isoproterenol induced concentration-dependent relaxation of phenylephrine-
contracted rings with a pD! 7.38 土（Ul (n=7) and this relaxation was significantly 
reduced in endothelium-denuded rings (pD:: 5,59 土 0.16’ n=6, P < 0.05 compared 
with that in the presence of endothelium). Low concentrations of isoproterenol 
produced a slight relaxant response (3.3 土 2.9 % and 7.6 土 3.3 % relaxation, 
respectively in 1 and 3 n M isoproterenol, n=4) without an effect on the basal tone. 
17p-Estradiol was previously shown to have an enhancing effect on the p-
adrenoceptors-mediated vasorelaxant responses (Ferrer et al., 1996). However, it is 
unknown whether 17p-estradiol and p-adrenoceptor agonists exert synergistic effects 
mutually. I therefore examined whether P-adrenoceptor agonists could also potentiate 
the relaxation induced by 17p-estradiol’ in both endothelium-intact and -denuded rat 
mesenteric arteries. The traces in Figure 19b show that the relaxation induced by 17p-
estradiol was enhanced after 60-minute pretreatment of low concentration of 
isoproterenol (1 nM), in comparison with the control (Figure 19a). Isoproterenol at 
two concentrations (1 and 3 nM) enhanced the 17P-estradiol-induced relaxation in 
endothelium-intact rings with the same potency (pD2 values: 5.06 土 0.06, n=8 for 
control; 5.97 士 0.14’ n=9 for 1 n M isoproterenol; 6.18 土 0.28，n=5 for 3 n M 
isoproterenol, P < 0.05 compared wjth control, Figure 20)，indicating that 1 n M is the 
concentration at which isoproterenol maximally enhanced the 17p-estradiol-induced 
relaxation. 
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In addition, the effect of isoproterenol (1 nM) was not different after the rings 
were exposed for 2.5 hours (pD2 value: 5.85 ± 0.22, n=7, P > 0.05 compared with that 
obtained in 1-hr incubation time, Figure 21). 
3.5.2. Role of endothelium/nitric oxide on the isoproterenol 
potentiation of 17 f3-estradiol-induced relaxation 
Isoproterenol-induced relaxation induced both endothelium-dependent and -
independent relaxation in rat mesenteric arteries (Huang & K wok, 1997). It is possible 
that low concentration of isoproterenol may release some relaxing factors from the 
endothelial layer and subsequently enhanced the relaxant response to 17~-estradiol. 
Therefore, I examined the role of endothelium/nitric oxide in isoproterenol enhancing 
effect on 17~-estradiol-induced relaxation. It was found that this effect was absent in 
the endothelium-denuded rings (pD2: 5.17 ± 0.07, n=7 for control and 5.31 ± 0.15 , 
n=6 for 1 nM isoproterenol, P > 0.05, Figure 22). 
To examine further the involvement of the endothelium, the effects of nitric 
oxide synthase inhibitors were investigated. Pretreatment with 30 J..lM L-NAME 
abolished the enhancing effect of isoproterenol completely (Figure 23 & 26). 
Furthermore, exposure to Rp8-cGMPS triethylamine (3 J..lM), a cyclic GMP-
dependent protein kinase inhibitor, partially but significantly, inhibited the effect of 
isoproterenol (pD2 value: 5.56 ± 0.13, n=6, P < 0.05 compared with the value 
obtained with isoproterenol alone, Figure 23 & 26). Both inhibitors had no effect on 
the basal tone or the maximal relaxation induced by 17~-estradiol {Figure 23). 
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Figure 19 � 
fTe'^l^'r- �howing the concentration-dependent relaxant responses to 
17P-estradiol in endothelium-intact rat mesenteric arteries in control (a) L in Z ring pretreated with 10'^  M isoproterenol (Iso) for n hour (b). 出e 
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Figure 20 � 
Concentration-response curves for 17p-estradiol-induced relaxation in endothelium-
intact rings pretreated with isoproterenol (Iso) for 60 minutes (〇’ n=8 in control; •’ 
n=8 in 1 n M isoproterenol; and • n=5 in 3 n M isoproterenol). Data are means ± 
S.E.M. of n different rings. 
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Figure 21 
Concentration-response curves for 17p-estradiol-induced relaxation in rings 
pretreated with 1 n M isoproterenol (〇，n=8 in control; •’ n=8 for 1 hour; and •， 
n=7 for 2.5 hours). Data are means ± S.E.M. of n different rings. ’ 
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Figure 22 
The concentration-response curves for 17p-estradiol-induced relaxation in the rat 
endothelium-denuded mesenteric artery rings pretreated with 1 n M isoproterenol (Iso) 
for 60 minutes (〇，n=5 for control; •，n=9 for isoproterenol). Data are means ± 
S.E.M. of n different rings. 
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Figure 23 
Effect of 30 n M L - N A M E on isoproterenol (Iso) enhancement of IVP-estradiol-
induced relaxation in endothelium-intact rings (〇，n=8 in control; •，n=8 in 1 n M 
isoproterenol; and •’ n=5 in L - N A M E plus 1 n M isoproterenol; •’ n=5 in 3 |iM Rp-
cGMPS triethylamine plus 1 n M isoproterenol). Data are means ± S.E.M. of n 
different rings. 
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3.5 J. Role of cyclic AMP on isoproterenol-enhancement of 17^ 
estradiol'induced relaxation 
Pretreatment with Rp-cAMPS triethylamine (3 |iM, 30-min contact time), 
the cyclic AMP-dependent protein kinase inhibitor, significantly inhibited the 
effect of isoproterenol (pD! value: 5.25 土 0.11，n=6, P < 0.05, compared with the 
value obtained with isoproterenol alone, Figure 24 & 26). 
Pretreatment of endothelium-intact rings with 3 n M forskolin (30-min 
contact time) also amplified the relaxation induced 17p-estradiol (Figure 25 & 26). 
Co-treatment with forskolin (3 nM) and isoproterenol (1 nM) did not have additive 
effect (pD2 values: 5.54 士 0.17, n=5 for forskolin and 5.71 土 0.09’ n=6 for 
forskolin plus isoproterenol, P > 0.05，Figure 25). Neither Rp-cAMPS nor 
forskolin at concentrations used affected the basal tone. 
3.5.4. Effects of (i-adrenoceptor antagonists 
Pretreatment with 3 |LLM propranolol (10 minutes before addition of 
isoproterenol), a non-selective P-adrenoceptor antagonist partially but significantly 
attenuated the effect of isoproterenol (Figure 27 & 30). ICI 118,551, a selective p2 
adrenoceptor, at 3 )JM almost abolished the effect of isoproterenol (pDz values: 
5.99 土 0.14，n=8 for isoproterenol and 5.29 土 0.14，n=6 for ICI 118,551 plus 
isoproterenol, P < 0.05，Figure 29 & 30). In contrast, 10 |LIM atenolol, a selective 
Pi-adrenoceptor antagonist, had no effect (Figure 28 & 30). None of three blocking 
agents influenced the basal tone or the relaxant response to 17P-estradiol (n=4-8， 
data not shown). 
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Figure 24 
The effect of Rp-cAMPS triethylamine on isoproterenol enhancement of 17(3-
estradiol-induced relaxation in endothelium-intact rings (〇，n=8 in control; •，n=8 in 
1 n M isoproterenol; and 口，n=6 in Rp-cAMPS triethylamine). Data are means 土 
S.E.M. of n different rings. 
-Page 70 - • 
Estroeen and Vascular C.nntractility / HY Chan 
§ 叫 。 C o n t r o l 
-a . • Forskolin 
X - • Iso + Forskolin / 
I ‘~~ I ‘‘ I I I LLL| 1~V I I "||| 1~I I I 1~I I I |||,| 
-8 -7 -6 -5 -4 -3 
Log [17p-Estradiol, M； 
Figure 25 
Effect of pretreatment with 3 n M forskolin on 17p-estradiol-induced relaxation in 
endothelium-intact rat mesenteric artery rings (〇，n=8 in control; •’ n=5 in 3 n M 
forskolin; and •，n=5 in 1 n M isoproterenol plus 3 n M forskolin). Data are means ± 
S.E.M. of n separate experiments. 
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Figure 26 
pD2 values were calculated as the negative logarithm of the 17p-estradiol 
concentration that produces 50% the maximal relaxation following various 
pharmacological interventions in the isolated rat mesenteric artery rings. Data are 
means 土 S.E.M. of n different rings. A significant difference (P < 0.05) is indicated by 
a between treatment and control groups and b between treatment and isoproterenol 
groups. 
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Figure 27 
Effects of propranolol on isoproterenol enhancement of 17|3-estradiol-induced 
relaxation in endothelium-intact rings, (a) The effect of 3 ^ M propranolol (〇’ n=8 in 
control; 11=8 in 1 n M isoproterenol; •，n=6 in propranolol plus isoproterenol. O 
n=8 in propranolol). Data are means 土 S.E.M. of n separate experiments. ’ ， 
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Figure 28 
The effect of 10 ^ iM atenolol on 17p-estradiol-induced contraction (〇，n=8 in control; 
n=:8 in 1 n M isoproterenol; •’ n=6 in atenolol plus isoproterenol. O n=4 in 
atenolol). Data are means 土 S.E.M. of n different rings. ’ ， 
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Figure 29 
The effect of 3 _ ICI 118,551 on 17P-estradiol-induced relaxation (〇’ n=8 in 
co，lirTi?f《i:l，isoproterenol; •’ n=6 in ICI 118,551 plus isoproterenol; 
n=:> in ICI 118,551). Data are means 土 S.E.M. of n different rings. 
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Figure 30 
pD2 values were calculated as the negative logarithm of the 17p-estradiol 
concentration that produces 50% the maximal relaxation following various 
pharmacological interventions in the isolated rat mesenteric artery rings. Data are 
means 土 S.E.M. of n different rings. A significant difference (P < 0.05) is indicated by 
a between treatment and control groups and b between treatment and isoproterenol 
groups. 
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3.6. Effect of Physiological Concentration of 17P-Estradiol 
on p-adrenoceptor Agonists-induced Relaxations in 
Porcine Coronary Artery 
Apart from the above-described experiments, another series of experiments 
were designed to examine whether 17p-estradiol would synergistically interact with 
P-adrenoceptor agonists. In these experiments, the isolated porcine coronary 
circumflex arteries were used. 
3.6.1. Effect of 17fi-estradiol on isoproterenol-induced relaxations 
Acute exposure of 17p-estradiol (0.3 and 1 nM) for 20 minutes did not 
influence the relaxant effect of isoproterenol (pD� values: 7.47 土 0.05 for control, n=6; 
7.42 土 0.17 for 0.3 n M IVp-Ez, n=6; 7.52 ± 0.11 for 1 n M 17p-E2, n=6, P > 0.05, 
Figure 31a). Pretreatment of the same concentration of 17P-estradiol for 1 hour had a 
small effect on isoproterenol-induced relaxations (pD� values: 7.47 土 0.1 for control, 
n=7; 7.62 土 0.08 for 0.3 n M 17P-estradiol, n=6; 7.8 土 0.05 for 1 n M IVP-estradiol, 
n=5，/^〉0.05，Figure 31b). 
3.6.2. Effect of 17^estradiol on fenoterol-induced relaxations 
The effect of IVP-estradiol on fenoterol (a P 2 - a d r e n e r g i c agonist)-induced 
relaxation was investigated. The concentration-response curve of fenoterol was 
unaffected following 20-minute pretreatment with two concentrations of 17p-estradiol 
� 
(0.3 and 1 nM) (P > 0.05，Figure 33a). However, 1-hr incubation with 0.3 n M 17p-
estradiol enhanced the fenoterol-induced relaxation (Figure 32), whilst neither 0.1 nor 
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Figure 31 
(a) Concentration-response curves for relaxation induced by isoproterenol after 
pretreatment with ivp-estradiol for 20 minutes in the endothelium-intact porcine 
coronary arteries (〇，n=6 for control; •，n=6 for 0.3 n M 17|3-estradiol; n=6 for 1 
n M np-estradiol). (b) Concentration-response curves for isoproterenol-induced 
relaxation after exposure to 17p-estradiol for 1 hour (〇，n=7 for control; •，n=6 for 
0.3 n M np-estradiol; •，n=6 for 1 n M 17p-estradiol). Data are means 土 S.E.M. of n 
different rings. 
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Figure 32 
Representative records showing the、concentration-dependent relaxant responses to 
fenoterol in endothelium-intact porcine coronary arteries in control (a) and in the ring 
pretreated with 0.3 n M 17p-estradiol for 1 hour (b). 
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Figure 33 
(a) Concentration-response curves for relaxation induced by fenoterol after 
pretreatment with 17p-estradiol for 20 minutes in the endothelium-intact porcine 
coronary arteries (〇,n=8 for control; •，n=6 for 0.3 n M 17p-estradiol; •，n=5 for 1 
n M 17p-estradiol). (b) Concentration-response curves for fenoterol-induced 
relaxation after exposure to 17P-estradiol for 1 hour (〇’ n=7 for control; •’ n=7 for 
0:1 n M 17p-estradiol; •， n = 7 for 0.3 n M 17P-estradiol; •， n = 8 for 1 n M 17p-
estradiol). Data are means 土 S.E.M. of n different rings. A significant difference 
between text and control values is indicated by asterisk* (P < 0.05). 
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1 n M ivp-estradiol had such effect (pD? values: 6.58 土 0.05 for control, n=7; 6.51 土 
0.07 for 0.1 nM, n=7; 7.02 土 0.05 for 0.3 nM, n=7, P < 0.05 compared with control; 
6.52 土 0.07 for 1 nM, n=8, Figure 33b & 36). 
Furthermore, the effect of tamoxifen was also examined. Figure 34 show that 
10 |i.M tamoxifen abolished the effect of 17p-estradiol on fenoterol-induced 
relaxation. It is clear that the concentration-response curve for fenoterol was shifted 
towards the control following exposure to tamoxifen (pDz values: 6.58 土 0.05 for 
control, n=7; 7.02 土 0.05 for 0.3 n M 17p-estradiol, n=7, P < 0.05 compared with 
control; 6.55 土 0.06 for 0.3 n M 17p-estradiol plus 10 |liM tamoxifen, n=5; 6.28 土 0.07 
for 10 |LIM tamoxifen alone, n=5, Figure 35 & 36). 
3.6J. Effect ofUP-estradiol on dobutamine-induced relaxations 
Figure 37a shows that 20-minute treatment with two concentrations of 17(3-
estradiol (0.3 and 1 nM) had no effect on dobutamine-induced relaxations. Similar 
pD2 values calculated from three concentration-response curves are: 6.02 ± 0.09 for 
control, n=5; 5.98 土 0.1 for 0.3 n M ivp-estradiol, n=5 and 6.09 土 0.1 for 1 n M 17(3-
estradiol, n=5 (P > 0.05). On the other hand, 1-hr exposure with 17(3-estradiol (0.1-1 
nM) had slightly inhibitory effect on the dobutamine-induced relaxations. However, 
the inhibitory effect was not significant in 0.1 n M 17p-estradiol treatment {P > 0.05 
when compared with control), whilst 0.3 and 1 n M 17p-estradiol had inhibitory effect 
(尸 < 0.05 when compared with control) (pD2 values: 6.13 土 0.2 for control, n=6; 5.64 
土 0.14 for 0.1 n M , n=5; 5.52 士 0.08 for 0.3 n M , n=7; 5.77 士 0.11 for 1 n M , n=7， 
Figure 37b). 
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Figure 34 
Representative records showing the effect of tamoxifen on the 1713-estradiol enhanced 
concentration-dependent relaxant responses to fenoterol in endothelium-intact porcine 
coronary arteries in the ring pretreated with 0.3 n M IVP-estradiol for 1 hr (a) and in 
the ring pretreated with 10 |LlM tamoxifen 10 minutes before adding 17p-estradiol (b). 
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Figure 35 
The effect of 17p-estradiol on fenoterol-induced relaxation for 1 hr (〇，n=7 for 
control; •，n=7 for 0.3 n M 17p-estradiol; •’ n=5 for 0.3 n M 17p-estradiol plus 10 
M M tamoxifen; •，n=5 for 10 |iM tamoxifen). Data are means ± S.E.M. of n different 
rings. A significant difference between text and control values is indicated by 
asterisk* (P < 0.05). 
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Figure 36 
pD2 values were calculated as the negative logarithm of the 17p-estradiol 
concentration that produces 50% the maximal relaxation following various 
pharmacological interventions in the isolated porcine coronary artery rings. Data are 
means 土 S.E.M. of n different rings. A significant difference (P < 0.05) is indicated 
by a between treatment and control groups; b between treatment and 0.3 n M 17B-
estradiol groups. The incubation time of all drugs is 1 hr. 
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Figure 37 
(a) Concentration-response curves for relaxation induced by dobutamine after 
pretreatment Ivp-estradiol for 20 minutes in the endothelium-intact porcine coronary 
arteries (〇，n=5 for control;參，n=5 for 0.3 n M Ivp-estradiol; •，n=5 for 1 n M 17p-
estradiol). (b) Concentration-response、curves for dobutamine-induced relaxation after 
exposure to 17(3-estradiol for 1 hr (〇’ n=6 for control; •’ n=5 for 0.1 n M 17(3-
estradiol; •，n=7 for 0.3 n M 17(3-estradiol; •，n=7 for 1 n M 17P-estradiol). Data are 
means 土 S.E.M. of n different rings. 
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Effect ofUji-estradiol on IBMX-induced relaxations 
The effect of 17P-estradiol on the relaxant response of 3-isobutyl-l-
methylxathine (IBMX), a potent phosphodiesterase inhibitor, was also investigated. It 
was found that pretreatment with 17p-estradioI (0.1-1 nM) for 20 minutes did not 
affect the concentration-response curve for DBMX-induced relaxation (pDs values: 
5.56 土 0.05 for control, n=8; 5.85 土 0.15 for 0.1 n M 17p-estradiol, n=5; 5.92 土 0.05 
for 0.3 n M np-estradiol, n=5; 5.82 土 0.08 for 1 n M 17p-estradiol, P > 0.05’ Figure 
38a). Meanwhile, similar results were obtained in the 1-hr pretreatment of 17p-
estradiol (pD: values: 5.92 土 0.08 for control, n=5; 5.95 土 0.08 for 0.3 n M 17(3-
estradiol，n=5; 6.06 土 0.16 for 1 n M 17p-estradiol, n=5, P > 0.05，Figure 38b). 
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Figure 38 
(a) The effect of 17p-estradiol on IBMX-induced relaxation following 20-minutes 
exposure in the endothelium-intact porcine coronary arteries (〇，n=8 for control. • 
n=5 for 0.1 n M 17p-estradiol; •，n=5 for 0.3 n M 17p-estradiol; •’ n=5 for I'nM 
17p-estradiol). (b) The effect of 17(3-ekradiol on IBMX-induced relaxation after 1-hr 
exposure (〇’ n=5 for control; •’ n=5 for 0.3 n M 17p-estradiol; n=5 for 1 n M 
17p-estradiol). Data are means 土 S.E.M. of n different rings. 
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3.7. Effect of Ovariectomy on the Vascular Reactivity 
3.7.L Effect of ovariectomy on the contractile activity of rat carotid 
arteries 
3-7,1.1. Effect of ovariectomy on phenylephrine-induced contraction 
In the endothelium-intact rat carotid arteries, phenylephrine (0.001-10 |liM) 
produced concentration-dependent increase in vessel tension. There was no significant 
difference in phenylephrine-induced contraction among the control (n=6), estrogen-
replaced (n=6, P > 0.05 when compared with the ovariectomized group), the 
ovariectomized group (n=6, P > 0.05 when compared with the control group) (Figure 
39). Figure 40a shows that there was no difference in sensitivity of arterial rings to 
phenylephrine among the control (n=6), ovariectomized (n=6) and tamoxifen-replaced 
groups (n=4, P > 0.05 when compared with either the control or ovariectomized 
groups). Similar results were observed among the ovariectomized (n=6)， 
ovariectomized estrogen-replaced (n=6, P > 0.05 when compared with co-treatment 
group), co-treatment of estrogen and tamoxifen group (n=6, P > 0.05 when compared 
with the ovariectomized group) (Figure 40b). 
However, the results with phenylephrine-induced response were different in 
� 
the endothelium-denuded rat carotid artery rings. The vasoconstriction effect of 
phenylephrine was significantly enhanced in ovariectomized rat carotid arteries. 
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Traces in Figure 41 show that lower concentrations (0.003-0.0 1 ~M) of phenylephrine 
produced vasoconstriction in the ovariectomized rats (Figure 41 b). In contrast, these 
two concentrations of phenylephrine did not induce measurable tension in the same 
ring preparation (Figure 41 a). Figure 42 shows the summarized data presented in 
concentration-response curves for phenylephrine among three groups of rats. It is 
clear that ovariectomy enhanced the contractile response to phenylephrine at 
concentrations ranging between 10 nM and 10 ~M (P < 0.05, between the control 
group, n=6, and the ovariectomized group, n= 12). Estrogen replacement treatment 
partially but significantly reversed the effect of ovariectomy. The effect of estrogen 
replacement became significant in contraction induced by phenylephrine at 
concentrations higher than 100 nM (Figure 42). The statistical analysis was performed 
and presented between the ovariectomized group (n=12) and the estrogen-replaced 
group (n=6) (Figure 42). 
I initially used tamoxifen pellet for the purpose of antagonizing the effect of 
chronic estrogen. Tamoxifen is a partial agonist on estrogen receptors, which could 
act as an antagonist in the presence of estrogen. However, to our surprise, tamoxifen 
pellet had the same effect as estrogen pellet on vascular contractility. Figure 43a 
shows that tamoxifen replacement therapy also partially reversed the enhancing effect 
of phenylephrine (0.3-1 0 ~M) in carotid arteries from the ovariectomized rats. There 
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is Statistical difference (P < 0.05) between the ovariectomized group (n=4) and the 
tamoxifen-replaced group (n=4). Furthermore, co-treatment with estrogen and 
tamoxifen caused additional reduction in the contractile response to phenylephrine 
(Figure 43b), suggesting that the chronic influence of ITP-estradiol and tamoxifen on 
vascular activity may be similar. 
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Figure 39 
The effect of ovariectomy (-Ov) on the phenylephrine-induced contractio~s in the 
endothelium-intact rat carotid arteries. Concentration-response curves for 
phenylephrine in the control group (0, n=6), the ovariectomized group (T , n=6) and 
the estrogen-replaced group (e, n=6). Data are means ± S.E.M. of n experiments. 
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The effect of estrogen or/and tamoxifen replacement treatment on phenylephrine-
induced contraction .in endothelium-intact carotid arteries of the ovariectomized rats. 
(a) Concentration-response curves for phenylephrine in the control group CO, 0=6), 
the ovariectomized group CT, 0=6) an~ the tamoxifen replaced group CA., n=4). Cb) 
Concentration-response curves for phenylephrine in the ovariectomized group CT, 
n=6), the estrogen replaced group Ce, n=6); the estrogen and tamoxifen replaced 
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Representative traces showing the contractile response to phenylephrine in 
endothelium-denuded carotid arteries of the control rat (a) and the ovariectomized rat 
(b). Force and time were indicated by calibration bars. 
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Figure 42 
The effect of ovariectomy on the phenylephrine-induced contraction in isolated 
endothelium-denuded rat carotid arteries. Concentration-response curves for 
phenylephrine in the control group (〇，n=6)，the ovariectomized group (•’ n=12) 
and the estrogen-replaced group (•, n=6). Statistical difference (P < 0.05) was 
indicated as a between the control and ovariectomized groups; b between the 
ovariectomized and estrogen-replaced groups. Data are means 土 S.E.M. of n 
experiments. 
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Figure 43 
The effect of estrogen or/and tamoxifen replacement treatment on phenylephrine-
induced contraction in endothelium-denuded carotid arteries from ovariectomized rats. 
(a) Concentration-response curves for phenylephrine in the control group (O, n=6), 
the ovariectomized group (•，ii=12)’ and the tamoxifen replaced group (•，n=4). 
The statistical difference (P < 0.05) was indicated as a between control and 
ovariectomized groups; b between the ovariectomized and tamoxifen-replaced groups. 
(b) Concentration-response curves、for phenylephrine in the estrogen replaced group 
(•，n=6), the ovariectomized group (•’ n=12), and estrogen and tamoxifen replaced 
•group (•，n=6). Statistical difference (P < 0.05) was indicated as a in between the 
ovariectomized and tamoxifen-replaced group; b between the ovariectomized and 
tamoxifen-replaced groups. Data are means 土 S.E.M. of n experiments. 
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3.7.1.2. Effect of ovariectomy on U46619-induced contraction 
In the endothelium-intact rat carotid arteries, the thromboxane A2 analogue, 
U46619 (1-300 nM) produced the contractile responses that were greater than that 
induced by phenylephrine. Ovariectomy did not affect the U46619-induced 
contraction (Figure 44). There is no significant difference among the control (n=6)， 
ovariectomized (n=6) and ovariectomized, estrogen-replaced groups (n=6) {P > 0.05， 
Figure 44). Figure 45a shows that tamoxifen replacement therapy had a slight 
inhibitory effect on U46619 (30 nM)-induced contraction in the ovariectomized rats. 
No significant difference can be detected in other concentrations used for U46619 
between the control and ovariectomized groups (P > 0.05, Figure 45a). Besides, co-
replacement therapy with estrogen and tamoxifen (n=6) did not alter the contractile 
response to U46619 (P > 0.05, among the ovariectomized, estrogen-replaced and co-
treatment groups (P > 0.05, Figure 45b). 
On the other hand, the vasoconstricting responses to U46619 in the 
endothelium-denuded carotid arteries were different from those in the endothelium-
intact rings even though the vessel tension developed by U46619 were similar (Figure 
44 & Figure 46). Figure 46 shows the concentration-response curves for U46619-
induced contraction in three treatment groups. It is clear that ovariectomy 
significantly potentiated U46619-mediated contraction (P < 0.05 between the control, 
n=6 and ovariectomized groups, n=6). Estrogen replacement treatment abolished this 
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enhancing effect of ovariectomy (Figure 46). Statistical difference in concentration-
response curves for U46619 is presented between the ovariectomized group (n=6) and 
ovariectomized, estrogen-replaced groups (n=6)(尸 < 0.05, Figure 46). 
Similar to the effect of tamoxifen pellet on phenylephrine-induced contraction, 
tamoxifen replacement treatment also fully reversed the enhancing effect of 
ovariectomy on vessel tone and this effect became apparent when the concentration of 
U46619 was greater than 10 n M (P < 0.05，n=5-6, Figure 47a). Figure 47b shows that 
co-treatment with estrogen and tamoxifen did not produce additive effect on U46619-
inudced contraction in the carotid arteries prepared from the ovariectomized rats (n=6, 
P > 0.05 compared with estrogen replacement group). 
V 
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Figure 44 
The effect of ovariectomy on the U46619-induced contraction in endothelium-intact 
rat carotid arteries. Concentration-response curves for U46619 in the control group 
'(0, n=6), the ovariectomized group CT, n=6) and the estrogen-replaced group ce, 
n=6). Data are means ± S.E.M. of n experiments. 
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Figure 45 
The effect of 17p-estradiol or/and tamoxifen treatment on U46619-induced 
contraction in endothelium-intact carotid arteries from the ovariectomized rats, (a) 
Concentration-response curves for U46619 in the control group (〇，n=6)’ the 
ovariectomized group (•，n=6) and the tamoxifen replaced group (•’ n=4). (b) 
Concentration-response curves for U46619 in the estrogen replaced group (•，n=6)， 
ovariectomized group (•，n=6); estrogen and tamoxifen replaced group (•’ n=6). 
Data are means 土 S.E.M. of n experiments. 
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Figure 46 
The effect of ovariectomy on U46619-induced contraction in endothelium-denuded 
rat carotid arteries. Concentration-response curves for U46619 in the control group 
(〇，n=6), the ovariectomized group (•, n=6), and the estrogen-replaced group ( •， 
n=6). Statistical difference was indicated as a between the control and ovariectomized 
groups; b between the ovariectomized and estrogen-replaced groups (P < 0.05). Data 
are means 土 S.E.M. of n experiments. 
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The effect of 17|3-estradiol or/and tamoxifen treatment on U46619-induced 
contraction in endothelium-denuded carotid arteries from the ovariectomized rats, (a) 
Concentration-response curves for U46619 in the control group (〇’ n=6), 
ovariectomized group (•，n=6) and tamoxifen replaced group (•，n=4). A significant 
difference (P < 0.05) is indicated by a between the control and ovariectomized groups; 
b between ovariectomized and tamoxifen-replaced groups, (b) Concentration-
response curves for U46619 in the estrogen-replaced group (•, n=6), ovariectomized 
group (•，n=6); estrogen and tamoxifen replaced group (•，n=6). Statistical 
•difference was indicated as a between the ovariectomized and estrogen-replaced 
groups; b is between the ovariectomized and co-treatment groups. Data are means 土 
S.E.M. of n experiments. 
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3.7丄 3. Effect of ovariectomy on high extracellular KUnduced contraction 
In the endothelium-denuded mesenteric arteries, the constrictor response to 
high extracellular K+ (5-80 m M ) was examined. The vasoconstriction induced high 
extracellular K+ was significantly enhanced in the ovariectomized rats (n=5). Traces 
in Figure 48 shows that 20 m M K+ produced an increase in vessel tension in an 
ovariectomized rat (Figure 48b), while this concentration of K+ produced much 
smaller contraction in a sham-operated rat (Figure 48a). Figure 49 shows the 
concentration-response curves for the high K+ response in endothelium-denuded rings. 
The curve was significantly shifted upwards in the ovariectomized rats (n=5 in each 
groups，P < 0.05 compared with control values. Figure 49). Estrogen replacement 
therapy completely abolished the effect of ovariectomy on the vascular response to 
high r (P > 0.05 between the control group, n=5 and estrogen-replaced group, n=5; 
P > 0.05 between the ovariectomized group and estrogen-replaced group, n=5, Figure 
49). 
Tamoxifen replacement therapy had a similar effect to estrogen. Figure 50a 
shows that chronic tamoxifen treatment totally reversed the enhancing effect on the 
high r contraction in the ovariectomized rats (P < 0.05 between the control, n=5 and 
ovariectomized group, n=5). Figure 50b shows that tamoxifen did not additional 
effect when implanted together with 17P-estradiol pellet. The two concentration-
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Figure 48 
Representative traces showing the contractile response to K+ in carotid arteries from a 
control rat (a) and an ovariectomized rat (b). 
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Figure 49 
The effect of ovariectomy on the high K^-induced contraction in rat endothelium-
denuded carotid arteries. Concentration-response curves for KCl (〇，n=5 for the 
control group; •，n=5 for the ovariectomized group and 參，n=5 for the estrogen-
‘ replaced group). A significant difference (P < 0.05) is indicated by a between the 
control and ovariectomized groups; b between the ovariectomized and estrogen-
replaced groups (P < 0.05). Data are means 土 S.E.M. of « experiments. 
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Figure 50 
The effect of 17|3-estradiol or/and tamoxifen treatment on high K+-induced 
contraction in endothelium-denuded carotid arteries from the ovariectomized rats, (a) 
Concentration-response curves for KCl (〇，n=5 for the control group; •，n=5 for the 
ovariectomized group; •，n=4 for the tamoxifen-replaced group). Significant 
difference is indicated by a between the control and ovariectomized groups; b is 
between the tamoxifen-replaced and ovariectomized groups, (b) Concentration-
response curves for KCl (鲁，n=5、fore the estrogen-replaced group; •，n=5 for the 
ovariectomized group; •，n=5 for the estrogen and tamoxifen cotreatment group). 
Statistical difference is indicated by a between the ovariectomized and estrogen-
replaced groups; b between the ovariectoimized and cotreatment groups (P < 0.05). 
Data are means ± S.E.M. of n experiments. 
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response curves for high K+ were identical (P < 0.05，n=5 in each groups). 
3-7.1.4. Effect of ovariectomy on acetylcholine-induced relaxation 
In endothelium-intact rat carotid arteries, the effect of ovariectomy on 
acetylcholine-induced relaxation was also examined. Figure 51 show that estrogen 
replacement therapy did not modify the endothelium-dependent relaxation induced by 
acetylcholine. The pD: values obtained from the three groups are very similar: 6.82 土 
0.08 for the control group, n=9; 7.12 土 0.09 for the ovariectomized group, n=4 and 
7.17 土 0.17，n=6 for the estrogen-replaced group (P > 0.05). 
In addition, chronic treatment with tamoxifen had no effect either. The p D� 
value obtained in Figure 52a: 6.82 土 0.08 for the control, n=9; 7.12 土 0.09 for the 
ovariectomized group, n=4; 6.74 土 0.09 for the tamoxifen-replaced group, n=6, P > 
0.05). 
Finally, co-treatment with estrogen and tamoxifen did not influence 
acetylcholine-mediated relaxant response (pD: values: 7.12 土 0.09 for the 
ovariectomized group, n=4; 7.17 ± 0.17 for the estrogen-replaced group, n=6; and 
7.30 ±0.11 for co-treatment with estrogen and tamoxifen, n=6) (P > 0.05，Figure 52b). 
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Figure 51 
The effect of ovariectomy on acetylcholine-induced relaxation in endothelium-intact 
.rat carotid arteries. Concentration-response curves for acetylcholine in the control (〇， 
n=9)’ the ovariectomized group (•，n=4) and the estrogen-replaced group (•，n=6). 
Data are means 土 S.E.M. of n experiments. 
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Figure 52 
The effect of 17(3-estradiol or/and tamoxifen treatment on acetylcholine-induced 
contractions in endothelium-intact carotid arteries from the ovariectomized rats, (a) 
Concentration-response curves for acetylcholine in the control group (〇，n=9)，the 
ovariectomized group (•，n=4), and the tamoxifen replaced group (•’ n=4). (b) 
Concentration-response curves for acetylcholine in the estrogen-replaced group ( •， 
n=6)’ the ovariectomized group (•’ n=4); the estrogen and tamoxifen replaced group 
(•’ n=6). Data are means 土 S.E.M. of n experiments. 
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Chapter 4 Discussion 
Women experience a dramatic increase in the incidence of coronary heart 
disease following the onset of menopause. Physiological levels of estrogen clearly 
exert cardioprotective effects since postmenopausal women receiving estrogen 
replacement therapy are less likely to develop heart disease. The beneficial effects of 
estrogen include lowering of low-density lipoprotein cholesterol and decreased 
vascular contractility. However, the precise pathways, and the cellular mechanisms by 
which female sex steroid hormones influence the activity of various vasculatures are 
incompletely understood. An increasing amount of evidence suggests that nitric oxide 
production, and modulation of the vascular responsiveness to endogenous 
vasoconstrictors or vasodilators may play an important role in the vascular effects of 
female sex steroid hormones. 
I specifically proposed the following hypotheses to be examined. (1) 
Endothelial nitric oxide may play a differential role in relaxations of arteries of 
different diameters induced by estrogen and progesterone. (2) P-Adrenoceptor 
agonists and 17p-estradiol may exert mutual synergistic effects on vessel tone. (3) Sex 
steroid hormones may inhibit protein kinase C-mediated contraction as a mechanism 
contributing to their vasodilator effects. (4) Acute exposure to physiological level of 
ivp-estradiol may modulate P-adrenoceptor-meidated vasorelaxation. (5) Chronic 
treatment with Ivp-estradiol may alter the vascular contractility. To this end, the 
experiments were carried out on several types of isolated rat arteries, {e.g. aorta, 
mesenteric artery in normal Sprague-Dawley rats and carotid artery from 
ovariectomized rats), and on the porcine coronary artery to investigate the vascular 
response to two female sex steroid hormones, 17p-estradiol and progesterone, by 
measuring changes in vessel tension with Grass force-displacement transducers. 
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4.1. Role of Endothelium/Nitric Oxide in 17p-Estradiol-
and Progesterone-induced Relaxations 
The relative protection from cardiovascular disease such as atherosclerosis and 
hypertension in pre-menopausal women is partly explained by the beneficial effects of 
estrogen (Stampfer et al, 1991) and it is believed that endothelial nitric oxide is one 
of the key mediators in the cardioprotective action of female sex steroid hormones. 
The present results show a different role of the functional endothelium in the relaxant 
response to IVP-estradiol or progesterone at supra-physiological concentrations in the 
conduit vessel (aorta) and the smaller-sized vessels (mesenteric artery). Nitric oxide 
contributes largely to the endothelium-dependent relaxation induced by 17p-estradiol 
in the isolated aortas or by progesterone in the mesenteric arteries. 
In the phenylephrine-preconstricted aortic rings, 17p-estradiol induced both 
endothelium-independent and -independent relaxation in a concentration-dependent 
manner. Removal of the endothelium decreased the IVp-estradiol-induced aortic 
relaxation by approximately 4-fold without an effect on the maximal relaxation (see 
Figure 9). L - N A M E or methylene blue reduced the 17p-estradiol-induced relaxation 
by a similar extent to that observed in the endothelium-denuded rings. The precursor 
of nitric oxide synthesis, L-arginine caused a full reversal of the inhibitory effect of L-
N A M E on 17p-estradiol-induced relaxation (see Figure 10). In rabbit aortas, 17p-
estradiol-induced relaxation involved endothelial nitric oxide (Ma et al, 1997). 
Estrogen was found to enhance N O release in rat aorta (Rahimian et al., 1997). In 
contrast，endothelium is seemingly not involved in 17p-estradiol-induced relaxation in 
•isolated rat mesenteric arteries since 17p-estradiol relaxed the preconstricted artery 
rings equi-effectively in both endothelium-intact and -denuded rings. Similarly, N^-
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nitro-L-arginine, another nitric oxide synthase inhibitor did not affect 17|3-estradiol-
induced relaxation in the pressurized rat small mesenteric arteries (Shaw et ai, 2000). 
The endothelium-independent relaxation to estrogen was also described in the 
coronary arteries from rats or rabbits (Jiang et al, 1991; Shaw et al, 2000). However, 
17p-estradiol-induced flow-dependent relaxation in rat small mesenteric arteries was 
partly mediated through release of endothelial nitric oxide (Cockell & Poston’ 1997). 
In some studies, the role of nitric oxide in modulating the vascular response to 
estrogen may be altered by the specificity of the vasoconstrictor used (Zhang & 
Davidge’ 1999) or by different experimental conditions. Nevertheless, our data 
indicate that in the isolated aortic rings but not mesenteric arteries, IVP-estradiol 
could act on the endothelium to release nitric oxide as a major mechanism mediating 
the endothelium-dependent aortic response. 
Another female sex hormone progesterone also produced concentration-
dependent relaxations in both aortic rings and mesenteric arteries. In contrast to the 
role of endothelium in the ITp-estradiol-induced relaxation, endothelium/nitric oxide 
only contributed to progesterone-induced relaxation in the isolated mesenteric arteries 
but not in the aortas (see Figure 12). Both L - N A M E and methylene blue attenuated 
progesterone-induced relaxation of mesenteric artery rings (see Figure 13). However, 
progesterone was reported to exert the endothelium-independent relaxation in rabbit 
and human arteries (Jiang .r al., 1992; Omar et al., 1995). It is not known whether 
this discrepancy is due to vessels prepared from different species. Chronic 
progesterone was actually found to attenuate estrogen-induced endothelium-
dependent relaxation in canine coronary arteries (Miller & Vanhoutte，1991)，however 
this effect cannot be observed in postmenopausal women (Gerhard et ai, 1998). L-
Arginine at 1 m M was less effective in antagonizing the effect of L - N A M E in 
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progesterone-induced relaxation of mesenteric arteries while this concentration of L-
arginine completely reversed the effect of L - N A M E on 17p-estradiol-induced aortic 
relaxation. It is at present unknown what had caused this discrepancy. It cannot be 
ruled out that L - N A M E may also exert a non-specific inhibitory effect against 
progesterone-induced relaxation. Non-specific effect of L - N A M E reported in 
endothelium-denuded rabbit coronary arteries was not affected by L-arginine (Buxton 
et al., 1993). 
The present results also show that 17P-estradiol and progesterone displayed 
different potency in relaxing isolated artery rings. 17p-Estradiol was approximately 3-
fold more potent in the aortas than in mesenteric arteries. In contrast, progesterone 
was about 2.5-fold more potent in mesenteric arteries than in aortas. This difference 
can be explained by at least one additional mechanism involved in female sex 
hormone-mediated relaxation, e.g. the involvement of endothelium/nitric oxide in the 
relaxant response of the aortas to 17P-estradiol or in the relaxant response of the 
mesenteric arteries to progesterone. 
Besides, the role of inducible nitric oxide in progesterone-induced relaxation 
was also examined. In the present study, the effect of A M T HCl at three 
concentrations (5，10 and 30 nM) was examined on progesterone-induced relaxation. 
In isolated rat mesenteric arteries with intact endothelium, A M T , a specific inhibitor 
of inducible nitric oxide synthase (iNOS), inhibited the progesterone-induced 
relaxation in a concentration-dependent manner (see Figure 14). Incubation with 30 
n M A M T decreased the progesterone-induced relaxation by approximately 4-fold 
without an effect on the maximal relaxation. Removal of endothelium completely 
.abolished the inhibitory effect of A M T , suggesting that involvement of endothelial 
iNOS in progesterone-induced relaxation if the concentrations of A M T used are 
-Page 112 - • 
Estroeen and Vascular Contractility / HY Chan 
Within the range that still selectively inhibits iNOS. iNOS was previously detected in 
endothelial cells (Kanno et al.’ 1994; Aliev et al., 1998). Both progesterone and 
estrogen were found to inhibit ovariectomy-induced expression of iNOS in female rat 
aortas (Tamura et al, 2000), however, the location of this effect in the arteries is yet 
to be determined. 
Taken together, I have provided some novel evidence for the different role of 
endothelium/nitric oxide in relaxations of arteries of different sizes (aortas and 
mesenteric arteries) induced by 17p-estradiol and progesterone. Endothelium/nitric 
oxide contributes significantly to 17p-estradiol-induced relaxation of the rat aortic 
rings or to progesterone-induced relaxation of the rat mesenteric arteries and this 
contribution to relaxation appears to only relate to lower concentrations of 17(3-
estradiol and progesterone. It is possible that estrogen and progesterone may stimulate 
release of endothelial nitric oxide in larger conduit vessels and smaller resistance-
sized vessels, respectively, to mediate the beneficial effect in the process of 
atherosclerosis and hypertension. Besides, endothelial iNOS may also play a role in 
the relaxant response to progesterone in rat mesenteric artery rings. However, the 
present studies were carried out on male rats only. Whether female counterparts 
would respond in a similar manner should be explored in the future. 
4.2. Effect of Estrogen Receptor Inhibitor on 17(3-
Estradiol-induced Relaxation 
In the present study, the effect of estrogen receptor inhibitor, ICI 182,780 was 
•examined on 17p-estradiol-induced relaxation. ICI 182,780 did not affect the 17p. 
estradiol-induced relaxation in endothelium-intact rat mesenteric arteries. Similar 
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result were also reported in the rat cerebral arteries (Salom et al., 2001) and 
mesenteric arteries (Shaw et al., 2000). However, ICI 182,780 was found to 
completely block the 176-estracliol-induced increase in intracellular [Ca!.] in cultured 
endothelial cell, but tamoxifen, an estrogen agonist/antagonist was devoid of effect 
(Rubio-Gayosso et al” 2000). Besides, prior administration of ICI 182,780 blocked 
the estrogen-induced changes in baroreflex sensitivity and autonomic tone (Saleh et 
a/.，2000). Other investigators also reported that ICI 182,780 could completely inhibit 
the estrogen-stimulated N O release (Yang et al., 2000; Kim et al., 1999). The 
discrepancy may be due to the difference in the receptor targets for ICI 182,780, 
estrogen receptor a and (3 forms in blood vessels (Pace et al., 1997). These data 
suggest that it is possible that the vascular response of different vessels to 17(3-
estradiol may be mediated through different sub-types of estrogen receptors. 
4.3. Interaction between Progesterone and 17p-Estradiol 
In the present study, supra-physiological concentrations of progesterone (0.3 
and 1 ^iM) were found to potentiate the 17p-estradiol-induced relaxation in 
endothelium-intact mesenteric artery rings (4-fold reduction in IC50 value, see Figure 
16) without affecting the maximal relaxation. However, this enhancing effect was 
abolished following removal of the endothelium, suggesting that progesterone 
increased the relaxant effect of 17p-estradiol via an endothelium-dependent 
mechanism. Due to the time constraint, no attempt was made to identify what 
endothelium-derived vasoactive factors may be involved in the potentiating effect of 
progesterone or to examine whether Ivp-estradiol should have the same effect as 
progesterone in rat mesenteric arteries. Paradoxically, other investigators reported that 
progesterone opposed the vascular effect of 17p-estradiol (Miyagawa et al.’ 1997). 
-Page 114-
Estroeen and Vascular Contractility / HY Chan 
Also, short-term exposure to 1 n M progesterone reduced the enhancing effects of 
17p-estradiol on the bradykinin and A23187-induced vasorelaxation (Teoh & Man, 
1999). This discrepancy may result from the different incubation time with 
progesterone. In my study, the arterial rings were allowed to incubate for 2.5 hours 
with progesterone; however, the incubation time of Teoh and Man's study was not 
more than 30 minutes. Moreover, the concentration of progesterone used in this study 
was much higher than 1 nM, a concentration used by Teoh and Man. Interestingly, the 
present results show that the presence of endothelium is required for the enhancing 
effect of progesterone. As discussed in Section 4.1., progesterone induced both 
endothelium-dependent and -independent relaxation, while 17(3-estradiol produced 
only endothelium-unrelated relaxation in the isolated rat mesenteric arteries. It is 
therefore possible that progesterone at 0.3 |iM may have released some N O in the 
endothelium, which then synergistically interact with 17p-estradiol. If this proves to 
be a case, low concentration of N O donors should also enhance estrogen-induced 
relaxation in the endothelium-denuded rings. This likelihood will be tested in the 
future study. 
4.4. Effects of Female Sex Steroid Hormones on Protein 
Kinase C-mediated Contraction 
Estrogen has been widely reported to relax blood vessels induced by various 
constrictors such as noradrenaline, endothelin, prostaglandins and angiotensin 11. 
Vasoconstriction induced by these agents are partly mediated through activation of 
protein kinase C (PKC) subsequent to production of diaceylglycerol, an endogenous 
stimulator of P K C in vascular SMC. It is therefore possible that estrogen may 
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interfere with PKC-dependent mechanism leading to vessel contraction. The present 
experiments were designed to test this possibility. PDA, an active phorbol ester which 
activates PKC, induced a slow-developing tension in endothelium-denuded rings 
bathed in Ca2+-free Krebs solution, indicating that PDA-induced contraction is not 
associated with Ca2+ influx; and P K C activation can interact with contractile filaments 
at the resting [Ca^li in vascular S M C (Huang, 1996). In Ca'-^ -containing Krebs 
solution，PDA induced similar level of vessel tone but the onset of response was faster, 
probably due to additional mechanisms involved. It was reported that Ca^ "" entry in 
vascular smooth muscle was activated during P K C activation by phorbol ester 
(Gleason & Flaim，1986). 
Ivp-Estradiol and progesterone produced concentration-dependent relaxation 
in rings contracted by P D A (see Figures 17 & 18) with the former being more 
effective. In the absence of extracellular Ca
2
+ ions, the relaxing effect of both 
hormones was significantly enhanced at most concentrations tested. 
In non-vascular preparations, 17(3-estradiol stimulated a Ca^^ influx in rat 
colonic crypts which was blocked in the presence of zero extracellular Ca�. (Doolan 
et 议，2000). It appears to a marked difference in the effect of estrogen on Ca^^ influx 
in vascular and non-vascular cells. 
4.5. Effects of p-Adrenoceptor Agonists on 17p-Estradiol-
induced Relaxations 
The results of this investigation provide evidence for the enhanced relaxant 
response to female sex steroid hormone, 17p-estradiol in the isolated rat mesenteric 
artery rings pretreated with low concentrations of isoproterenol, a non-selective (3-
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adrenoceptor agonist. It is known that isoproterenol induces both endothelial nitric 
oxide-dependent and -independent relaxation in the coronary arteries of other species 
(Parent et al, 1993; Luer al, 1995). 
It appears that this enhancing effect is dependent on the presence of the 
functional endothelium since removal of the endothelium or inhibition of nitric oxide 
synthase by L - N A M E abolished the effect of isoproterenol (see Figures 22 & 23). 
Moreover, pretreatment with the membrane permeable inhibitor of cyclic G M P -
dependent protein kinase, Rp-cGMPS triethylamine also significantly attenuated the 
isoproterenol-induced potentiation. On the other hand, the endothelium was not 
involved in 17p-estradiol-induced relaxant response in the same preparations (Chan et 
a/” 2001). The role of endothelial nitric oxide in isoproterenol-induced relaxation was 
demonstrated in rat mesenteric arteries (Graves & Poston, 1993; Huang et al” 1998) 
and rat aorta (Gray & Marshall，1992; Delpy et al., 1996). L - N A M E or methylene 
blue (an inhibitor of guanylyl cyclase) significantly reduced the relaxant response to 
p-adrenoceptor agonists or forskolin, an adenylyl cyclase inhibitor in these blood 
vessels. Forskolin also induced endothelium-dependent aortic relaxation (Gray & 
Marshall, 1992; Toyoshima et al, 1998), indicating a role of endothelial nitric oxide 
in relaxation initiated by cyclic AMP-elevating dilators. 
M y data demonstrate that isoproterenol-induced potentiation of 17p-estradiol-
induced relaxation was abolished by Rp-cAMPS triethylamine, a membrane 
permeable protein kinase A inhibitor (see Figure 24). Pretreatment with low 
concentration of cyclic AMP-elevating agent, forskolin, also amplified the relaxant 
effect of 17p-estradiol in endothelium-intact rings (see Figure 25). These results 
“suggest that the effect of isoproterenol may be mediated through cyclic A M P -
dependent mechanism in the endothelium. Both isoproterenol and forskolin 
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stimulated production of cyclic A M P and cyclic G M P in endothelium-intact rat aortic 
rings (Gray & Marshall, 1992). 
Crosstalk may occur between cyclic G M P - and cyclic AMP-dependent 
cellular pathways. Low concentrations of nitrovasodilators exerted marked 
synergistic interaction with isoproterenol, enhancing isoproterenol-induced aortic 
relaxation (Delpy et ai, 1996; Maurice et al., 1991). Reciprocally, isoproterenol and 
forskolin were reported to potentiate sodium nitropmsside-induced increase in cyclic 
G M P levels in rat brain capillary endothelial cells (Vigne et ai, 1994). In cultured 
porcine aortic endothelial cells, isoproterenol and forskolin amplified bradykinin- and 
ATP-induced formation and secretion of endothelium-derived relaxing factor; this 
effect corresponded to the enhanced cyclic AMP-elevating agent-induced increase in 
intracellular free Ca
2
+ concentration (Graier et al” 1992). These studies suggest the 
presence of extensive crosstalk among cyclic A M P , cyclic G M P and probably also 
Ca2+-signaling mechanisms to jointly regulate endothelial functions. In isolated 
canine coronary microvessels, isoproterenol, forskolin and bromo-cyclic A M P 
increased nitric oxide production. Both L - N A M E and Rp-cAMPS markedly inhibited 
the nitric oxide release induced by these cyclic AMP-elevating agents. Forskolin also 
enhanced nitric oxide production stimulated by bradykinin in coronary blood vessels 
(Zhang & Hintze，2001). These new findings indicate a cyclic AMP-dependent 
endothelial nitric oxide-forming pathway in coronary blood vessels, which may play 
an important role in the regulation of vessel tone. This may explain the endothelium-
dependent component of the relaxant responses to other endogenously occurring 
cyclic AMP-elevating transmitters and neuropeptides such as adrenomedullin and 
• calcitonin gene-related peptides in some mammalian blood vessels (Gray & Marshall, 
1992; Hayakawa et al., 1999). 
-Page 118-
Estroeen and Vascular C.nntractility / HY Chan 
In rat aortic rings, the relaxant response to isoproterenol or dibutyryl A M P 
was inhibited by L-NAME. Isoproterenol-induced relaxation was associated with 
increases in tissue cyclic A M P and cyclic G M P contents. L - N A M E reduced 
isoproterenol-induced increase in cyclic G M P but not cyclic A M P levels (Toyoshima 
过 al., 1998). It seems that the relaxant response of rat aorta to cAMP-mediated 
vasodilators is mediated at least in part through nitric oxide production in 
endothelium and subsequent increase in cyclic G M P in vascular smooth-muscle cells. 
Our results indicate that isoproterenol-induced increase in endothelial cyclic A M P 
level may enhance the basal nitric oxide production and release, which subsequently 
interacts synergistically with 17p-estradiol to produce greater relaxation. Therefore, 
the amplifying effect of isoproterenol could be mimicked by forskolin and abolished 
by the inhibitors of either protein kinase A or nitric oxide synthase. To certain degree 
current data support a previous study in which histamine-induced nitric oxide release 
was significantly reduced by Rp-cAMPS, suggesting that in porcine aortic endothelial 
cells, nitric oxide-mediated vasodilation might be caused by production of cyclic 
A M P initiated through the histamine H-receptors (Kishi et al., 1998). 
Both (3i and p2-adrenoceptor agonists produced endothelium-dependent and 一 
independent relaxation in rat mesenteric arteries (Huang & Kwok，1997; Huang et al., 
1998) and in rat aorta (Toyoshima er al., 1998). Stimulation of cyclic A M P formation 
in the endothelium by isoproterenol, leading to direct or indirect release of nitric oxide, 
was reported by Gray and Marshall (1992); however, the subtype of the (3-
adrenoceptors involved was not further determined. The present results show that 
isoproterenol-induced enhancement was partially antagonized by propranolol (see 
“Figure 27)，a non-selective P-adrenoceptor antagonist but almost completely inhibited 
by ICI 118,551 (see Figure 29), a selective p2-adrenoceptor antagonist (O'Donnell & 
-Page 119 -
Estroeen and Vascular Contractility / HY Chan 
Wanstall，1981). In contrast, atenolol, a selective pi-adrenoceptor antagonist 
(O'Donnell & Wanstall，1981) did not influence the effect of isoproterenol. These 
results clearly point to a primary role for P2-adrenoceptors in the enhanced relaxant 
response to 17p-estradiol in isoproterenol-pretreated rings. M y results support a 
recent in vivo study with perfused rabbit femoral artery (Xu et al., 2000). 
Isoproterenol decreased prefusion pressure via stimulation of p2-adrenoceptor subtype. 
Injection of L - N A M E abolished the pressure response to isoproterenol and 
significantly suppressed the pressure response to forskolin and dibutyryl cyclic A M P 
(Xu et al, 2000). These results together with m y findings again indicate that P2-
adrenergic stimulation and cyclic A M P elevation activate a nitric oxide-producing 
pathway in mammalian arteries in vitro and in vivo. 
In summary, I have provided novel mechanistic evidence for the isoproterenol 
potentiation of 17p-estradiol-induced relaxant response in rat mesenteric arteries. 
Isoproterenol may stimulate endothelial p2-adrenoceptors to elevate basal nitric oxide 
release via a cyclic AMP-dependent mechanism on the endothelium. This increased 
level of nitric oxide then interacts synergistically with cellular mechanisms initiated 
by np-estradiol. There may exist a crosstalk linkage between cyclic A M P and cyclic 
G M P in the endothelium, which could play an important role in the control of vessel 
tone by more than two endogenous dilators utilizing cyclic nucleotide-mediated 
intracellular pathways. This has been the first attempt to investigate the synergistic 
interaction between ^ adrenoceptor agonists and estrogen in the arterial rings in vitro. 
It is unclear whether sympathetic neurotransmistters such as adrenaline and 
noradrenaline at physiological levels would enhance the vasodilator effect induced by 
17p-estradiol at circulating concentrations in vivo. 
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4.6. Effects of 17p-Estradiol on p-Adrenoceptor Agonists-
induced Relaxations in Porcine Coronary Artery 
Considerable evidence suggests that (3-adrenoceptors are subject to regulation 
by sex steroid hormones. For example, intrauterine application of 17p-estradiol 
significantly up-regulated expression of guinea-pig myometrial P-adrenoceptors 
(Hatijis et al, 1989). Progesterone increased the number of p-adrenoceptors in the 
brain of adult, ovariectomized rats (Maggi et al, 1985). Estrogen and progesterone 
exerted synergistic effect in increasing the P-adrenoceptor density in rat heart 
(Klangkalya and Chan, 1988). The similar influence of estrogen or progesterone on 
the number of p-adrenoceptors was also observed in rabbit lung tissue (Moawad et ai, 
1982) and rat liver (Yagami et ai, 1994). Ferrer et ai (1996) provided evidence that 
estrogen replacement enhanced p-adrenoceptor-mediated relaxation in rat mesenteric 
arteries. It was suggested that estrogen replacement potentiated vascular responses 
induced by P-adrenoceptor activation by an endothelium-independent mechanism 
(Ferrer et al, 1996)，even though isoproterenol was reported to induce both 
endothelium-dependent and -independent relaxation in the same preparations (Huang 
& Kwok，1997). The same research group also described that estrogen replacement 
enhanced vasoconstriction induced by smooth-muscle a^-adrenoceptor activation, 
although this effect was obscured in intact vessels due to an overriding influence of 
endothelial dilator substances, primarily NO. In mesenteric arteries from 
ovariectomized rats, smooth muscle was less sensitive to ocradrenoceptor agonist 
stimulation，however, the release of a vasoconstrictor prostanoid from the 
endothelium was predominant, and induced significant vasoconstriction. (Ferrer & 
Osol，1998). P-Adrenoceptor is present on both smooth-muscle (Asano et al, 1991) 
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and endothelial cells (Molenaar et al, 1988). However, no experiment has examined 
the effect of acute exposure to physiological concentrations of estrogen on B-
adrenoceptor -mediated vasorelaxation in mammalian arteries. 
The major observation in this series of experiments is that the relaxant 
response to p2-adrenoceptor activation with fenoterol was significantly enhanced by 
short-term incubation (1 hr) with 0.3 n M 17(3-estradiol in the isolated porcine 
coronary circumflex arteries (see Figure 32 & 33b). The concentration of 0.3 n M falls 
into the reported circulating level of estrogen ranging between 0.1 and 1 n M in the 
body (Abraham et al, 1972; Rosano et al, 1993; Gilligan et al, 1994). In contrast, 
20-min exposure to 17(3-estradiol (0.1-1 nM) was without effect on |32-adrenoceptor-
induced response. Low concentrations of estrogen also appeared to slightly enhance 
isoproterenol-induced relaxation following 1-hr incubation. Fenoterol is a selective 
Pradrenoceptor agonist, which induced both endothelium-dependent and -
independent vasorelaxation (Huang & Kwok’ 1997)，while isoproterenol is a non-
selective p- (pi and p2) adrenoceptor agonist. This difference may partly explain a 
greater potentiating effect of estrogen on relaxation induced by fenoterol than 
.isoproterenol if Pradrenoceptor-mediated response is predominant in the porcine 
coronary arteries. It is interesting to note that 1 n M ivp-estradiol (1-hr exposure) did 
not modulate fenoterol-mediated coronary relaxation. It is not known whether 
estrogen may have different modulatory effect on p-adrenoceptor-mediated cellular 
response depending upon the concentration used. Alternatively, estrogen exhibits 
differential sensitivity in different steps in intracellular second messenger pathways 
X 
activated by Pradrenoceptor stimulation in intact blood vessels. Further experiments 
are apparently required to examine whether higher concentrations of estrogen (> 10 
nM) could have inhibitory effect on p2-adrenoceptor-mediated vasorelaxation. Even 
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though P,-adrenoceptor agonist such as dobutamine also caused vasorelaxant effect 
(Huang et al., 1998), short-term exposure to estrogen (0.1-1 nM, either 20-min or 1-hr) 
did not enhance dobutamine-induced relaxation in porcine coronary arteries. Instead, 
1-hr incubation with 17p-estradiol reduced relaxation induced by dobutamine (see 
Figure 37). If 0.3 n M estrogen enhanced p2-adrenoceptor-mediated relaxation on one 
hand，and reduced pradrenoceptor-mediated relaxation on the other hand, it would be 
not surprising to observe a marginal effect of estrogen on relaxation induced by 
isoproterenol (see Figure 31)，an agonist that activates both p, and Pradrenoceptors 
in blood vessels. 
M y results were inconsistent with a previous study with non-vascular smooth 
muscle. 17p-Estradiol was found to increase the isoproterenol-induced relaxation but 
not the fenoterol-induced relaxation in the porcine bronchus (Foster et al, 1983). 
These discrepancy likely results from the difference in experimental tissues used in 
these two studies. Other studies with non-vascular tissues demonstrated that 
lymphocyte fc-adrenceptor function in normal females was under the cyclical 
influence of ovarian sex steroids, with greater P^-adrenceptor density and c A M P 
response to isoproterenol during the luteal phase than the follicular phase. These 
effects were associated with elevated post-ovulatory levels of progesterone and 
estrogen (Wheeldon et al., 1994). 
The present results also show that the enhancing effect of 0.3 n M estrogen on 
fenoterol-induced relaxation can be reversed by 10 _ tamoxifen, a reported mixed 
estrogen agonist/antagonist. Tamoxifen produced a small but insignificant inhibition 
V 
of fenoterol-induced response and no explanation could be provided at present. This 
indicates that tamoxifen may not act in the same manner as estrogen, otherwise, both 
compounds should have similar effect on the relaxant response to Ps-adrenoceptor 
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agonist. It remains to be verified whether the antagonistic effect of tamoxifen is 
mediated through binding to the sites as the same as for estrogen in vascular tissue. 
Tamoxifen has been recently demonstrated to relax rabbit coronary arteries via an 
endothelial NO- and estrogen receptor-dependent mechanism (Figtree et al, 2000). 
Tamoxifen was also found to inhibit voltage-operated Ca""^  channels in vascular 
smooth muscle cells and this mechanism may contribute to its inhibitory effect on 
vasoconstriction (Song et al., 1996). 
Increased levels of c A M P are thought to mediate p-adrenoceptor-induced 
vasorelaxation (Phomchirasilp & Lockwood, 1977). Estrogen, (supra-physiological 
level)-mediated endothelium-independent relaxation may be also partly caused by 
elevated c A M P contents in blood vessels (Mugge et al, 1993). However, the 
physiological concentration of 17p-estradiol was found to have no effect on cAMP 
contents in porcine coronary smooth muscle cells (Christ et al., 1999). In order to 
examine the possibility that the enhancing effect of estrogen on fenoterol-induced 
relaxation is associated with intracellular c A M P that could be raised by (3-
adrenoceptor stimulation, the effect of acute IVP-estradiol was tested on relaxation 
induced by IB M X ， a phosphodiesterase inhibitor. Short-term exposure to 0.1-1 n M 
estrogen did not have a significant effect despite 20-min incubation with estrogen 
seems to have a slight enhancing effect. However, it was reported that ivp-estradiol 
enhanced the relaxant potency of another phosphodiesterase inhibitor, theophylline 
(Foster et al.’ 1983). More experiments are certainly needed to examine this 
hypothesis by measuring c A M P in endothelium-intact porcine coronary arteries under 
the same treatment as that in contraction experiments. 
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4.7. Effect of Ovariectomy on the Vascular Reactivity 
A previous study showed that the maximal pressor response to phenylephrine 
is greatly attenuated in aortas from female rats as compared with that from male rats 
(Stallone, 1993). In addition, 17p-estradiol was shown to significantly decrease the 
contractile response to phenylephrine in aortic rings of male rats (Thomas et al., 
1995). Long-term 17P-estradiol treatment reduced the contraction of rat aorta to 
phenylephrine (Andersen et al, 1999). These data indicate that long-term inhibitory 
influence of estrogen on adrenergically mediated vasoconstriction. In order to 
investigate whether physiological levels of estrogen in rat arteries could modify the 
constrictor response, I also examined the impact of ovariectomy and 17p-estradiol 
replacement therapy on the vascular reactivity in normal control rats and 
ovariectomized female rats. The common carotid artery was used which may 
resemble the properties of cerebral arteries supplied by the internal carotid artery. 
The present study shows that in endothelium-intact carotid arteries, 
ovariectomy did not significantly affect the concentration-dependent contractile 
response to phenylephrine even though phenylephrine-induced tension tended to 
increase. 17(3-Estradiol replacement treatment brought back this small enhancing 
effect. In contrast, the phenylephrine-induced contraction was markedly increased in 
ovariectomized rats and this enhancement can be partially inhibited by 17p-estradiol 
replacement (see Figure 42). It is unknown whether partial inhibition by chronic 
estrogen is due to more dominating effect of phenylephrine on the endothelium 
following ovariectomy. Meyer et al. reported that endothelium-intact mesenteric 
arteries from estrogen-replaced rats were significantly less sensitive to phenylephrine 
(Meyer et al., 1997; Zhang & Davidge, 1999). Some explanations were given that oti-
adrenergic receptor expression may be decreased in the mesenteric arteries from 17|3-
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estradiol-replaced rats as compared with those from the ovariectomized animals 
(Zhang & Davidge, 1999). Furthermore, the maximal binding of ai-adrenoceptors in 
cardiac ventricles was found to be greater in male than in female Dahl rats (Hayahi et 
al” 1995). However, this potential mechanism can not explain my results with 
phenylephrine since phenylephrine produced greater contractile response in 
endothelium-denuded rings than endothelium-intact rings in three groups of rats. One 
possibility is that ai-adrenoceptor-mediated endothelium-dependent relaxing effect 
may remain intact or even enhanced in the ovariectomized carotid arteries. This effect 
would apparently counteract with increased contractility in S M C induced by 
phenylephrine. An endothelium-dependent response was observed in vascular 
response to both oci and a2-adrenoceptor stimulation (Tabemero et al, 1999; Nishina 
et al, 1999). 
These data are consistent with a report by Binko and Majewski who showed 
that 24-hour incubation with 17|3-estradiol of isolated endothelium-denuded aortic 
rings from ovariectomized rats attenuated the phenylephrine-induced constriction 
(Binko & Majewski，1998). In addition, this attenuation was also observed even the 
treatment was shortened to 6 hours (Binko et al., 1998). Paradoxically, other 
researchers reported no difference in phenylephrine-induced contraction in 
endothelium-denuded mesenteric arteries (Meyer et ai, 1997) or rat aorta (Andersen 
ef aL, 1999) between the ovariectomized and estrogen-replaced groups. The exact 
cause between this difference is unclear, but it may related to different arteries used 
by different research groups or different methods used for chronic estrogen treatment 
(injection of low concentrations of estrogen or estrogen pellet implantation which 
allows stable daily release of estrogen). 
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Similar to the results with phenylephrine, U46619-induced contraction 
remains the same in rat carotid arteries prepared from the control, ovariectomized and 
estrogen-replaced groups (see Figure 44). Similar data were also obtained in rat 
mesenteric arteries in which the vascular response to U46619 did not differ between 
the estrogen-pretreated and ovariectomized rats (Zhang & Davidge，1999). In addition, 
Miller and Vanhoutte described failure of estrogen to modify the vascular contractility 
to U46619 in the rabbit aortas (Miller & Vanhoutte, 1990). In contrast, one study did 
show that estrogen potentiated the responsiveness of mesenteric arteries to U46619 in 
male rats (Vargas et al.’ 1995). 
On the other hand, when the endothelium was mechanically denuded, the 
contractile response to U46619 was increased in the ovariectomized rats compared 
with the control rats (see Figure 46). This enhancement was completely reversed by 
estrogen replacement therapy. Similar results were reported in the endothelium-
denuded coronary and renal arteries in which U46619 produced higher vessel tension 
in male than female dogs (Karanian & Ram well, 1996). In addition, estrogen 
treatment in male dogs decreased the pressor response of U46619 (Karanian & 
Ramwell, 1996). These findings again indicate that function of the endothelium may 
be normal or even enhanced, as a result, the increased contraction of S M C to U46619 
or phenylephrine may have been masked in the endothelium-intact rings. 
In addition to phenylephrine and U46619, I also examined the effect of high 
K+ on vessel tone to rule out the possibility that changes in vascular contractility is 
associated with vasoconstrictors whose action is mediated by intracellular second 
messengers. In endothelium-denuded carotid arteries, both maximal arterial 
• contraction and sensitivity to K+ were increased in the ovariectomized rat (see Figure 
49). The effect of ovariectomy on high response was totally inhibited by estrogen 
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replacement. Andersen et al. reported that the maximal aortic contraction to K+ was 
attenuated in the estrogen-replaced rats (Andersen et al., 1999). Moreover, high K+-
induced contraction was smaller in aortas from the pregnant rats (Honda et al., 1996), 
indicating the chronic influence of estrogen in the body on Ca""" influx through plasma 
membrane Ca^ "^  channels. 
Another novel finding of the present study is that tamoxifen replacement 
therapy displayed the same effect as estrogen replacement therapy on vascular 
contractility. In the endothelium-denuded rings, the magnitude of the contractile 
response to phenylephrine, U46619, or high K+ is similar in three groups of rats, e.g. 
the control, estrogen-replaced and tamoxifen-replaced groups (see Figures 43’ 47 & 
50). However, contradictory results were presented that tamoxifen increased the 
pressor response to U46619 in the endothelium-denuded arteries of female dogs 
(Karanian & Ramwell’ 1996). Besides, chronic co-treatment with estrogen and 
tamoxifen did not have additive effect on contraction induced by U46619 or high K+. 
But co-treatment seems to have a greater effect on phenylephrine-induced contraction 
than single treatment (see Figure 43). These new results clearly indicate that chronic 
tamoxifen may not act as an anti-estrogen, rather, it behaves like an estrogenic agent. 
The present study also examined influence of ovariectomy on the 
endothelium-dependent relaxation in the rat carotid arteries. Acetylcholine produced 
concentration-dependent relaxation, which was sensitive to inhibition of inhibitors of 
NOS. This relaxation was unaltered in the ovariectomized rats (see Figure 51). There 
was no difference in acetylcholine-induced relaxation in the control, ovariectomized, 
estrogen-replaced, tamoxifen-replaced groups and co-treatment with estrogen and 
tamoxifen (see Figure 52). These data agreed with the results obtained by White et al. 
who showed that the concentration-response curve to acetylcholine in left carotid 
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arteries was similar in male, vehicle-treated female and 17P-estradiol-supplemented 
female rats (White er al., 1997). In addition, other investigators demonstrated that 
chronic treatment with estrogen did not influence the acetylcholine-induced relaxation 
of rat aorta (Meyer et al, 1997). However, conflicting data have also been provided. 
Prolonged treatment with estrogen potentiated the acetylcholine-induced relaxation in 
rat aorta (Cheng et al., 1994; Binko & Majewski, 1998; Andersen et al., 1999), rabbit 
femoral arteries (Gisclard et al； 1988), canine coronary arteries (Miller & Vanhoutte， 
1991), and guinea pig heart (Thompson et ai, 2000). In addition, the relaxant 
response to acetylcholine was greater in the aortas from the pregnant rats than non-
pregnant rat (Honda et al., 1998). Cheng et ai explained that the enhanced 
acetylcholine-induced responses may be due to depressed acetylcholinesterase activity 
(Cheng et al., 1994). Whatever mechanisms are involved in improved acetylcholine-
medi^ted relaxation by estrogen in a number of arteries, m y results do not suggest the 
modulatory effect of chronic estrogen on acetylcholine-induced endothelium-
dependent relaxation under m y experimental condition. However, this piece of data, 
together with results with vasoconstrictors, provides additional information 
suggesting the endothelium may function normally after ovariectomy. It would be 
better to have examined the endothelium-dependent relaxation in different arterial 
rings to see whether there is regional difference in vasculature in response to 
acetylcholine or other endothelium/nitric oxide dilators. Unfortunately, I was unable 
to perform all these experiments due to the time constraint. 
4.8. Conclusions 
In conclusion, m y results have provided some novel findings concerning the 
arterial effects of female sex steroid hormones. Firstly, the endothelial nitric oxide 
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plays different role in the relaxant response to 17p-estradiol and progesterone in the 
conduit vessel (aorta) and the smaller-sized vessels (mesenteric artery). Endothelial 
nitric oxide contributes largely to the endothelium-dependent relaxation induced by 
17p-estradiol in the isolated aortas or by progesterone in the mesenteric arteries. 
� 
Secondly, 17p-estradiol-induced relaxation in the mesenteric arteries was enhanced 
by isoproterenol, primarily through activation of P2-adrenoceptors. Pretreatment with 
inhibitors of nitric oxide activity, such as L - N A M E or Rp-8-cGMPS eliminated or 
markedly inhibited the effect of isoproterenol, suggesting that isoproterenol may act 
on the endothelial cells to release nitric oxide and cyclic GMP-dependent pathway 
was involved in the effect of isoproterenol. Cyclic AMP-dependent mechanism in 
endothelium was also involved in the effect of isoproterenol. These new findings 
suggest that p2-adrenergic agonist and 17(3-estradiol can synergies each other via 
several intracellular second messengers primarily in the endothelium. Thirdly, both 
17p-estradiol and progesterone concentration-dependently reduced the contractile 
response to the activator of protein kinase C, indicating an additional cellular 
mechanism by which steroid hormones reduce vessel tone evoked by PKC-dependent 
constrictors such as phenylephrine, endothelin and angiotensin 11. Fourthly, acute 
exposure to physiological level of 17p-estradiol enhanced Pz-adrenoceptor-mediated 
relaxation. Finally, ovariectomy and chronic 17p-estradiol altered the vascular 
reactivity in mainly endothelium-denuded arteries. These data suggest that chronic 
treatment of 17(3-estradiol may modulate the properties of smooth muscle but not of 
endothelial cells. 
� 
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